[
  {
    "id": "mrd-1",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 30,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 3,
    "sampleCollectionNotes": "Quest test directory for Haystack MRD monitoring lists three 10 mL cfDNA tubes (≈30 mL total) as standard collection; minimum acceptable volume ~24 mL.",
    "sampleCitations": "https://testdirectory.questdiagnostics.com/",
    "name": "Haystack MRD",
    "vendor": "Quest Diagnostics",
    "approach": "Tumor-informed",
    "method": "Whole-genome–derived personalized panel; ~50 variants tracked; low error suppression",
    "cancerTypes": [
      "Multi-solid"
    ],
    "indicationsNotes": "Tumor-informed MRD assay for multiple common and rare solid tumors; Quest/Resolution MRD platform, FDA Breakthrough Device designation.",
    "sensitivity": 95.0,
    "sensitivityCitations": "https://haystackmrd.com/",
    "sensitivityNotes": "Headline 95% sensitivity is analytical; clinical sensitivity by stage not yet published from large prospective cohorts.",
    "sensitivityStagesReported": "Analytical validation (stages not specified)",
    "specificity": 100.0,
    "specificityCitations": "https://haystackmrd.com/clinicians/ | https://doi.org/10.1016/S1525-1578(24)00232-0",
    "specificityNotes": "Analytical specificity of 100% with zero false positives reported. ⚠️ Analytical validation; clinical specificity from large cohorts pending. (J Mol Diagn 2024;26(11):S100)",
    "analyticalValidationWarning": true,
    "validationCohortStudy": "J Mol Diagn 2024 (analytical validation)",
    "stageIISensitivity": null,
    "stageIISensitivityNotes": "FDA Breakthrough Device designation specifically for Stage II CRC (Aug 2025); stage-specific clinical sensitivity data expected from ongoing trials.",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Stage III-specific data not yet published; NCT07125729 head-to-head vs Signatera includes Stage II–IV CRC.",
    "landmarkSensitivityCitations": "https://haystackmrd.com/faq/",
    "longitudinalSensitivityCitations": "https://haystackmrd.com/",
    "lod": "6 ppm",
    "lod95": "6 ppm (≈0.0006% tumor fraction)",
    "lod95Citations": "https://testdirectory.questdiagnostics.com/test/test-guides/TS_HaystackMRD/haystack-mrd",
    "lodCitations": "https://haystackmrd.com/ | https://testdirectory.questdiagnostics.com/test/test-guides/TS_HaystackMRD/haystack-mrd",
    "lodNotes": "LoD95 (95% limit of detection) is ~6 ppm (0.0006% tumor fraction). This represents the ctDNA level at which 95% of replicates are detected as positive in analytical validation studies.",
    "requiresTumorTissue": "Yes",
    "requiresMatchedNormal": "Yes",
    "variantsTracked": "50",
    "variantsTrackedCitations": "https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq300",
    "variantsTrackedNotes": "Up to ~50 tumor-specific variants selected from tumor and matched-normal whole-exome sequencing; variants filtered to avoid CHIP-associated regions.",
    "initialTat": 30.0,
    "initialTatCitations": "https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq300",
    "initialTatNotes": "Baseline tumor+normal whole-exome profiling and panel design typically ~4 weeks (~30 days) from sample receipt.",
    "followUpTat": 7.0,
    "followUpTatCitations": "https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq300",
    "followUpTatNotes": "Post-baseline MRD blood draws generally reported within about 5–7 days (Quest/Haystack FAQs; Quest Q&A sometimes quotes 7–10 days).",
    "bloodVolume": 30.0,
    "bloodVolumeCitations": "https://testdirectory.questdiagnostics.com/test/test-detail/13151/haystack-mrd-monitoring",
    "bloodVolumeNotes": "Quest test directory for Haystack MRD monitoring lists three 10 mL cfDNA tubes (≈30 mL total) as standard collection; minimum acceptable volume ~24 mL.",
    "tat": 30.0,
    "tatCitations": "https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq300",
    "tatNotes": "Overall paradigm: ~4 weeks for initial panel build, ~1 week for subsequent MRD timepoints.",
    "fdaStatus": "CLIA LDT (Quest Diagnostics); FDA Breakthrough Device designation for stage II colorectal cancer (Aug 2025).",
    "reimbursement": "Coverage emerging (~70% of tests reimbursed); Medicare pilot for CRC plus growing commercial coverage.",
    "reimbursementNote": "As of mid-2025, Quest reports ~70% of Haystack MRD tests are reimbursed across payers. Medicare pilot coverage in place for CRC, with active engagement with CMS for broader LCD. Commercial payer coverage growing; patient access programs available.",
    "cptCodes": "0561U",
    "clinicalAvailability": "Clinical LDT – shipping",
    "clinicalTrials": "NCT07125729 (150; resectable stage II–IV CRC; Haystack vs Signatera head-to-head); NCT06979661 (25; MRD-PORT trial; post-op stage II–III NSCLC; Haystack MRD-guided RT); NCT05798663/AFT-57 (158; unresectable stage III NSCLC; atezolizumab ± tiragolumab CRT; Haystack MRD used for correlative MRD analyses)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT07125729 | https://clinicaltrials.gov/study/NCT06979661 | https://clinicaltrials.gov/study/NCT05798663",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical MRD assessment and longitudinal surveillance. Clinical trials focus on post-operative and surveillance settings in CRC and NSCLC.",
    "totalParticipants": 333,
    "numPublications": 17
  },
  {
    "id": "mrd-2",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Monitoring commonly uses two 10 mL Streck cfDNA tubes (≈20 mL total); baseline also requires FFPE tumor tissue and matched-normal blood.",
    "sampleCitations": "https://www.personalis.com/next-personal/",
    "name": "NeXT Personal Dx",
    "vendor": "Personalis",
    "approach": "Tumor-informed",
    "method": "Tumor-informed, whole-genome-based MRD assay: WGS of tumor and matched normal identifies up to ~1,800 patient-specific variants, which are tracked at high depth in plasma to detect ctDNA down to ~1–3 parts per million (ppm).",
    "cancerTypes": [
      "Breast",
      "Colorectal",
      "NSCLC"
    ],
    "indicationsNotes": "Personalis NeXT Personal Dx tumor-informed MRD assay. Medicare-covered for early-stage breast cancer recurrence monitoring; clinical data also reported in colorectal cancer and NSCLC.",
    "sensitivity": 100,
    "sensitivityCitations": "https://investors.personalis.com/static-files/ef5485c7-4866-449d-9dcb-bfaf081bf97d",
    "sensitivityNotes": "100% sensitivity reported in validation cohort (n=493). Value represents analytical validation; larger clinical cohorts ongoing.",
    "analyticalValidationWarning": true,
    "sensitivityStagesReported": "Not separately reported (small validation cohort)",
    "stageIISensitivity": null,
    "stageIISensitivityNotes": "Stage-specific sensitivity not reported; validation cohort too small for stage breakdown.",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Stage-specific sensitivity not reported.",
    "specificity": 99.9,
    "specificityPlus": true,
    "specificityCitations": "https://investors.personalis.com/static-files/ef5485c7-4866-449d-9dcb-bfaf081bf97d",
    "specificityNotes": ">99.9% specificity in validation cohort (n=493).",
    "validationCohortSize": 493,
    "validationCohortStudy": "Personalis analytical validation cohort (2024)",
    "longitudinalSensitivity": null,
    "longitudinalSensitivityCitations": "https://investors.personalis.com/static-files/ef5485c7-4866-449d-9dcb-bfaf081bf97d",
    "longitudinalSensitivityNotes": "Reported as 100% in validation cohort; value set to null pending larger studies.",
    "longitudinalSpecificity": null,
    "longitudinalSpecificityCitations": "https://investors.personalis.com/static-files/ef5485c7-4866-449d-9dcb-bfaf081bf97d",
    "longitudinalSpecificityNotes": "Reported as 100% in validation cohort; value set to null pending larger studies.",
    "lod": "1.67 ppm",
    "lod95": "3.45 ppm",
    "lod95Citations": "https://www.personalis.com/next-personal-assay-performance/",
    "lodCitations": "Northcott et al. Oncotarget 2024; https://www.personalis.com/next-personal-assay-performance/",
    "lodNotes": "Detection threshold is 1.67 ppm; LOD95 (95% confidence) is 3.45 ppm. The gap between these values means serial testing can catch lower-level disease.",
    "leadTimeVsImaging": 450.0,
    "leadTimeVsImagingCitations": "https://pubmed.ncbi.nlm.nih.gov/39848827/ | Garcia-Murillas et al. Ann Oncol 2025; TRACERx NSCLC data",
    "leadTimeVsImagingNotes": "450 days (15 months) is the median lead time from the Garcia-Murillas et al. Ann Oncol 2025 early-stage breast cancer cohort (range 0.9-61.5 months). This is the median from this specific study, not a universal NeXT median across all indications. NSCLC TRACERx data showed ~6 months.",
    "vendorRequestedChanges": "2025-12-03: Personalis requested lead time update to 15 months (450 days) based on Ann Oncol 2025 breast cancer paper (Garcia-Murillas et al.). Verified against source and updated.",
    "requiresTumorTissue": "Yes",
    "requiresMatchedNormal": "Yes",
    "variantsTracked": "1800",
    "variantsTrackedCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10939476/",
    "variantsTrackedNotes": "Personalized panels track on the order of 1,800 tumor-specific variants per patient based on tumor/normal whole-genome sequencing, with additional investigational content in some implementations.",
    "initialTat": 21.0,
    "initialTatCitations": "Vendor data (Dan Norton, Personalis, Dec 2025)",
    "initialTatNotes": "Initial report turnaround is 21 days per vendor (Dan Norton, Personalis, Dec 2025).",
    "followUpTat": 10.0,
    "followUpTatCitations": "Vendor data (Dan Norton, Personalis, Dec 2025)",
    "followUpTatNotes": "Follow-up monitoring draws reported within 10 days per vendor (Dan Norton, Personalis, Dec 2025).",
    "bloodVolume": 20.0,
    "bloodVolumeCitations": "https://www.personalis.com/asset/specimen-preparation-guide-blood/",
    "bloodVolumeNotes": "Monitoring commonly uses two 10 mL Streck cfDNA tubes (≈20 mL total); baseline also requires FFPE tumor tissue and matched-normal blood.",
    "tat": 21.0,
    "tatCitations": "Vendor data (Dan Norton, Personalis, Dec 2025)",
    "tatNotes": "Initial report: 21 days; follow-up monitoring: 10 days (vendor-confirmed Dec 2025).",
    "fdaStatus": "CLIA LDT (early access / clinical offering)",
    "reimbursement": "Medicare coverage for stage II-III breast cancer MRD surveillance; additional solid tumor coverage via Tempus xM collaboration expanding.",
    "cptCodes": "MolDX with DEX Z-code",
    "clinicalAvailability": "Clinical LDT – shipping (initial market availability)",
    "exampleTestReport": "https://www.personalis.com/wp-content/uploads/2024/07/NeXT-Personal-Dx-Clinical-Report-Template-DOC-002568B.pdf",
    "clinicalTrials": "NCT06230185 (422); VICTORI study interim cohort (~71)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT06230185",
    "clinicalSettings": ["Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical MRD, post-adjuvant assessment, and longitudinal surveillance. Medicare coverage specifically for breast cancer recurrence monitoring/surveillance setting.",
    "totalParticipants": 493,
    "numPublications": 4,
    "numPublicationsPlus": true
  },
  {
    "id": "mrd-3",
    "sampleCategory": "Blood/Plasma",
    "sampleTubeType": "LBgard",
    "sampleCollectionNotes": "3 LBgard cfDNA tubes required for blood draw; tissue required at baseline",
    "name": "Oncodetect",
    "vendor": "Exact Sciences",
    "approach": "Tumor-informed",
    "method": "Tumor-informed hybrid-capture ctDNA assay: tumor plus matched-normal sequencing to select up to ~200 somatic variants per patient, followed by targeted hybrid-capture NGS with CHIP-aware filtering.",
    "cancerTypes": [
      "Multi-solid"
    ],
    "indicationsNotes": "Exact Sciences Oncodetect tumor-informed circulating tumor DNA (ctDNA) MRD test, marketed for use across solid tumors; designed for post-surgical and surveillance use cases.",
    "sensitivity": 91.0,
    "sensitivityCitations": "https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2025/New-Evidence-Validates-Oncodetects-Ability-to-Detect-Molecular-Residual-Disease-and-Predict-Recurrence-in-Colorectal-Cancer-Patients/default.aspx",
    "sensitivityNotes": "In CRC, results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring periods to date, showed the Oncodetect test achieved 78% sensitivity at the post-surgical timepoint and 91% sensitivity during the surveillance monitoring period, with specificities of 80% and 94%, respectively.",
    "sensitivityStagesReported": "Stage II–III combined (CRC)",
    "stageIISensitivity": null,
    "stageIISensitivityNotes": "Stage II-specific CRC sensitivity not separately reported in Alpha-CORRECT publications; combined with Stage III. Stage-specific breakdowns would be informative for treatment decisions.",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Alpha-CORRECT cohort primarily Stage III CRC; stage-specific breakdown not published.",
    "stageDataExpected": true,
    "specificity": 94.0,
    "specificityCitations": "https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2025/New-Evidence-Validates-Oncodetects-Ability-to-Detect-Molecular-Residual-Disease-and-Predict-Recurrence-in-Colorectal-Cancer-Patients/default.aspx",
    "specificityNotes": "In CRC (Alpha-CORRECT study), Oncodetect demonstrated specificities of 80% at the post-surgical timepoint and 94% during surveillance monitoring.",
    "ppv": 50.0,
    "ppvCitations": "https://www.exactsciences.com/-/media/project/exact-sciences/websites/cancer-testing/oncodetect/white-papers/oncodetect_mrd-informed_post-surgical_crc_white-paper_04-2024_updated_05-2025.pdf",
    "ppvNotes": "CRC postsurgical 3y PPV 50% (Alpha-/Beta-CORRECT).",
    "npv": 96.0,
    "npvCitations": "https://www.exactsciences.com/-/media/project/exact-sciences/websites/cancer-testing/oncodetect/white-papers/oncodetect_mrd-informed_post-surgical_crc_white-paper_04-2024_updated_05-2025.pdf",
    "npvNotes": "CRC postsurgical 3y NPV 96%.",
    "landmarkSensitivity": 78.0,
    "landmarkSensitivityCitations": "https://investor.exactsciences.com/news-releases/news-release-details/exact-sciences-reports-first-quarter-2025-financial-results",
    "landmarkSensitivityNotes": "CRC postsurgical sensitivity.",
    "landmarkSpecificity": 80.0,
    "landmarkSpecificityCitations": "https://investor.exactsciences.com/news-releases/news-release-details/exact-sciences-reports-first-quarter-2025-financial-results",
    "longitudinalSensitivity": 91.0,
    "longitudinalSensitivityCitations": "https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2025/New-Evidence-Validates-Oncodetects-Ability-to-Detect-Molecular-Residual-Disease-and-Predict-Recurrence-in-Colorectal-Cancer-Patients/default.aspx",
    "longitudinalSensitivityNotes": "CRC surveillance sensitivity.",
    "longitudinalSpecificity": 94.0,
    "longitudinalSpecificityCitations": "https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2025/New-Evidence-Validates-Oncodetects-Ability-to-Detect-Molecular-Residual-Disease-and-Predict-Recurrence-in-Colorectal-Cancer-Patients/default.aspx",
    "longitudinalSpecificityNotes": "CRC surveillance specificity.",
    "lod": "15 ppm",
    "lod95": "15 ppm",
    "lod95Citations": "https://www.exactsciences.com/cancer-testing/oncodetect-mrd-providers | https://www.exactsciences.com/-/media/project/exact-sciences/websites/cancer-testing/oncodetect/validation/oncodetect_limit-of-detection_08-2024_updated_05-2025.pdf",
    "lodNotes": "LoD 15 ppm (0.0015% tumor fraction) with high-end inputs. Observed detection down to 2 ppm seen in clinical validation studies. Per Exact Sciences: 'To minimize false negatives in most clinical scenarios, the limit of detection should be below 100 PPM (0.01% TF).'",
    "lodCitations": "https://www.exactsciences.com/cancer-testing/oncodetect-mrd-providers | https://www.exactsciences.com/-/media/project/exact-sciences/websites/cancer-testing/oncodetect/validation/oncodetect_limit-of-detection_08-2024_updated_05-2025.pdf",
    "leadTimeVsImaging": 317.0,
    "leadTimeVsImagingNotes": "Median lead time ~10.4 months (~317 days) from first MRD-positive Oncodetect result to radiologic recurrence in the α-CORRECT stage III CRC cohort. This is the median from this specific study, not a universal value across all indications.",
    "leadTimeVsImagingCitations": "https://investor.exactsciences.com/news-releases/news-release-details/exact-sciences-announces-positive-topline-results-alpha-correct | Exact Sciences α-CORRECT press release",
    "requiresTumorTissue": "Yes",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "White paper: WES tumor + matched-normal buffy coat.",
    "variantsTracked": "200",
    "variantsTrackedNotes": "Panel tracks up to 200 tumor-specific variants per patient (median ~170) with roadmap to higher-plex designs.",
    "initialTat": 28.0,
    "initialTatNotes": "Provider-facing materials describe baseline tissue+normal discovery and panel creation in roughly 4 weeks.",
    "followUpTat": 10.0,
    "followUpTatNotes": "Monitoring blood draws typically result within about 10 days after sample receipt.",
    "bloodVolumeNotes": "3 LBgard cfDNA tubes required for blood draw; tissue required at baseline",
    "tat": 28.0,
    "tatNotes": "Approximate baseline TAT ~4 weeks; subsequent MRD timepoints ~10 days.",
    "fdaStatus": "CLIA LDT",
    "reimbursement": "Medicare (CRC only)",
    "reimbursementNote": "Medicare MolDX coverage for colorectal cancer MRD only (announced July 2025). Not covered for other cancer types. Broader payer adoption evolving.",
    "cptCodes": "PLA pending",
    "cptCodesNotes": "Payer policies vary.",
    "clinicalAvailability": "Clinical LDT – shipping",
    "independentValidation": "Yes",
    "independentValidationNotes": "Prospective Alpha-/Beta-CORRECT CRC cohorts.",
    "exampleTestReport": "https://www.exactsciences.com/-/media/project/headless/one-exact-web/documents/products-services/oncodetect/providers/sample-report-stage-iii-escalation.pdf?rev=10365d7a28c8467eb25d253943ce8fe9",
    "clinicalTrials": "NCT06398743 (416); α-CORRECT observational study (124)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT06398743",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical MRD assessment (78% sensitivity) and longitudinal surveillance (91% sensitivity) in CRC per Alpha-CORRECT study.",
    "totalParticipants": 540,
    "numPublications": 1,
    "numPublicationsPlus": true
  },
  {
    "id": "mrd-4",
    "sampleCategory": "Blood/Plasma",
    "name": "Pathlight",
    "vendor": "SAGA Diagnostics",
    "approach": "Tumor-informed",
    "method": "Tumor-informed MRD platform using whole-genome profiling to identify structural variants (SVs) and other truncal events, which are then tracked using sensitive digital PCR and/or NGS in serial plasma samples.",
    "cancerTypes": [
      "Breast",
      "Multi-solid"
    ],
    "indicationsNotes": "SAGA Diagnostics Pathlight tumor-informed MRD assay. Medicare coverage announced for breast cancer across all subtypes (HR+/HER2-, HER2+, and triple-negative); platform positioned as multi-cancer MRD.",
    "sensitivity": 100,
    "sensitivityCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "sensitivityNotes": "100% sensitivity in TRACER study validation cohort (n=100, stage I-III breast cancer). ⚠️ Small cohort size; larger validation ongoing.",
    "specificity": 100,
    "specificityCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "specificityNotes": "100% specificity in TRACER study validation cohort (n=100). ⚠️ Small cohort size; larger validation ongoing.",
    "smallSampleWarning": true,
    "validationCohortSize": 121,
    "validationCohortStudy": "TRACER study (Clinical Cancer Research, Jan 2025; expanded cohort SABCS 2025)",
    "landmarkSensitivity": null,
    "landmarkSpecificity": null,
    "longitudinalSensitivity": 100,
    "longitudinalSensitivityCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "longitudinalSensitivityNotes": "100% longitudinal sensitivity in TRACER breast cohort (n=100).",
    "longitudinalSpecificity": 100,
    "longitudinalSpecificityCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "longitudinalSpecificityNotes": "100% longitudinal specificity in TRACER breast cohort (n=100).",
    "lod": "0.001% VAF",
    "lod95": "~5 ppm",
    "lod95Citations": "https://sagadiagnostics.com/wp-content/uploads/2024/12/SABCS-Poster_v3.pdf",
    "lodCitations": "https://sagadiagnostics.com/wp-content/uploads/2024/12/SABCS-Poster_v3.pdf",
    "lodNotes": "Detection threshold ~0.001% VAF (~10 ppm); LoD95 ~5 ppm in analytical studies of SV-based assays.",
    "leadTimeVsImaging": 411.0,
    "leadTimeVsImagingCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "leadTimeVsImagingNotes": "Early-stage breast cancer cohort data highlight median lead time ≈13.7 months (~411 days) between MRD positivity and clinical/radiologic recurrence.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Tumor-informed (WGS of tumor); structural variants tracked by dPCR.",
    "requiresMatchedNormal": "Yes",
    "initialTat": 14,
    "initialTatCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "initialTatNotes": "~2 weeks for initial result; faster than many tumor-informed assays due to SV-based approach.",
    "followUpTat": 5,
    "followUpTatCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-u-s-commercial-launch/",
    "followUpTatNotes": "Subsequent blood tests typically ~3-5 days.",
    "tat": 14,
    "tatNotes": "Initial results in ~2 weeks; follow-up monitoring in ~3-5 days.",
    "fdaStatus": "CLIA LDT (US) with international laboratory service offerings.",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage via MolDX (Palmetto GBA) positive determination July 30, 2025. Covered for recurrence monitoring in stage II-III breast cancer across all subtypes (HR+/HER2-, HER2+, TNBC) for up to 6 years surveillance. Coverage based on TRACER study evidence (100% sens/spec, 13.7-month lead time).",
    "reimbursementCitations": "https://sagadiagnostics.com/saga-diagnostics-announces-medicare-coverage-for-pathlight-mrd-test-in-breast-cancer-across-all-subtypes/ | https://www.genomeweb.com/cancer/saga-diagnostics-mrd-test-receives-medicare-coverage-breast-cancer-recurrence-monitoring",
    "cptCodes": "No dedicated PLA as of 2025; payer-specific coding applies.",
    "cptCodesNotes": "Contact vendor for current billing guidance.",
    "clinicalAvailability": "Clinical LDT – shipping (select geographies)",
    "clinicalTrials": "TRACER study (cTdna evaluation in eaRly breAst canCER); Clinical Cancer Research Jan 2025 (n=100), SABCS 2025 expanded cohort (n=121). CLAIRE (NCT pending - surveillance study in ER+/HER2- breast). CATER (MRD-guided capecitabine trial).",
    "clinicalTrialsCitations": "https://doi.org/10.1158/1078-0432.CCR-24-3472 | https://www.businesswire.com/news/home/20251201531260/en/SAGA-Diagnostics-Showcases-New-Pathlight-MRD-Data-at-SABCS-2025",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "TRACER study validated longitudinal MRD surveillance in early-stage breast cancer with lead time ~13.7 months vs imaging.",
    "totalParticipants": 121,
    "totalParticipantsNotes": "TRACER expanded cohort (SABCS 2025): 121 patients with TNBC, HER2+, or ER+/HER2- early breast cancer.",
    "numPublications": 8,
    "numPublicationsPlus": true
  },
  {
    "id": "mrd-5",
    "sampleCategory": "Blood/Plasma",
    "name": "RaDaR ST",
    "vendor": "NeoGenomics",
    "approach": "Tumor-informed",
    "method": "Tumor-informed MRD assay on the InVision/ RaDaR platform: tumor and matched-normal sequencing identify up to 48 variants, which are tracked by deep NGS with error suppression.",
    "cancerTypes": [
      "Breast",
      "Head & Neck",
      "Multi-solid"
    ],
    "indicationsNotes": "NeoGenomics RaDaR ST tumor-informed MRD assay with Medicare coverage for HR+/HER2- breast cancer (including late recurrence >5 years) and HPV-negative head and neck cancer; supportive data across multiple solid tumors.",
    "sensitivity": 95.7,
    "sensitivityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10870111/",
    "sensitivityNotes": "RaDaR ST demonstrated 97% concordance and maintained equivalent sensitivity with RaDaR 1.0. In breast, 95.7% sensitivity and 91.0% specificity.",
    "specificity": 91.0,
    "specificityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10870111/",
    "specificityNotes": "RaDaR ST demonstrated 97% concordance with RaDaR 1.0. In breast cancer validation, specificity was 91.0%.",
    "lod": "~10 ppm",
    "lodCitations": "https://ir.neogenomics.com/news-events/press-releases/detail/310/neogenomics-to-present-radar-st-bridging-study-at-islb-2025-demonstrating-reliable-mrd-detection-across-solid-tumors",
    "lodNotes": "Analytical validation for the RaDaR assay supports reliable detection around 10 ppm with ≥70–90% sensitivity at that level in contrived samples.",
    "requiresTumorTissue": "Yes",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "Buffy coat matched normal used for germline filtering in studies.",
    "variantsTracked": "48",
    "variantsTrackedNotes": "Tracks up to 48 patient-specific variants.",
    "initialTat": 35.0,
    "initialTatNotes": "NeoGenomics materials typically describe baseline discovery and panel build in ~5 weeks.",
    "followUpTat": 7.0,
    "followUpTatNotes": "Serial MRD monitoring blood draws generally reported within ~7 days after receipt.",
    "tat": 35.0,
    "tatNotes": "Approximate TAT ~5 weeks baseline, ~1 week longitudinally.",
    "fdaStatus": "CLIA LDT",
    "reimbursement": "Medicare coverage for selected indications; MolDX framework applied.",
    "reimbursementNote": "LCDs describe coverage in specific solid tumors (e.g., breast and HPV-negative head & neck cancer) with broader multi-tumor positioning in trials.",
    "commercialPayers": ["Blue Shield of California"],
    "commercialPayersCitations": "https://www.decibio.com/",
    "commercialPayersNotes": "Blue Shield of California covers RaDaR for MRD testing. Coverage continues to expand as clinical evidence builds.",
    "cptCodes": "PLA under consideration.",
    "cptCodesNotes": "Contact vendor for current billing guidance.",
    "clinicalAvailability": "Clinical LDT – shipping",
    "clinicalTrials": "ISLB 2025 bridging study, 'Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types'; 166 patients across 15 solid tumor types; 97% concordance with RaDaR 1.0",
    "clinicalSettings": ["Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical MRD, post-adjuvant, and surveillance monitoring. Medicare coverage for HR+/HER2- breast cancer (including late recurrence >5 years) and HPV-negative head and neck cancer.",
    "totalParticipants": 166,
    "numPublications": 10,
    "numPublicationsPlus": true
  },
  {
    "id": "mrd-6",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleVolumeCitations": "https://www.guardanthealth.com/solutions/guardant-reveal/",
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Commonly collected as two 10 mL Streck cfDNA tubes (≈20 mL).",
    "sampleCitations": "https://www.guardanthealth.com/solutions/guardant-reveal/",
    "name": "Reveal MRD",
    "vendor": "Guardant Health",
    "approach": "Tumor-naïve",
    "method": "Tumor-naïve, blood-only ctDNA MRD test using epigenetic tumor fraction (epiTF) detection on Guardant Infinity platform. Analyzes over 19,000 differentially methylated loci for mutation-agnostic ctDNA detection. Detects residual disease and recurrence without requiring tumor tissue.",
    "cancerTypes": [
      "Colorectal",
      "Breast",
      "Non-small cell lung cancer (NSCLC)"
    ],
    "indicationsNotes": "Guardant Reveal MRD tumor-naïve ctDNA test for early-stage cancer MRD detection and recurrence monitoring after curative-intent treatment. Medicare coverage for CRC; breast and NSCLC coverage expanding.",
    "sensitivity": 81.0,
    "sensitivityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11443202/",
    "sensitivityNotes": "COSMOS 2024 longitudinal sensitivity for stage II+ CRC is ~81%. Earlier landmark/Reinert 2021 data showed 55-63% sensitivity. Headline value reflects current COSMOS longitudinal performance.",
    "sensitivityStagesReported": "Stage II–IV combined",
    "stageIISensitivity": null,
    "stageIISensitivityNotes": "Stage II-specific sensitivity not separately reported; combined with stages III–IV in headline figures. Stage-specific data would help clinicians counsel Stage II patients.",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Stage III-specific sensitivity not separately reported.",
    "stageDataExpected": true,
    "specificity": 98.0,
    "specificityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11443202/",
    "specificityNotes": "COSMOS 2024 longitudinal specificity is 98% for CRC. Earlier landmark data showed 100% specificity but with serial/longitudinal testing, 91-98% is more representative.",
    "landmarkSensitivity": 63.0,
    "landmarkSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/",
    "landmarkSensitivityNotes": "CRC landmark sensitivity (stage II–III).",
    "landmarkSpecificity": 98.0,
    "landmarkSpecificityCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/",
    "landmarkSpecificityNotes": "CRC landmark specificity (stage II–III); updated from 100% to align with longitudinal data.",
    "longitudinalSensitivity": 81.0,
    "longitudinalSensitivityCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-COSMOS-Study-Published-in-Clinical-Cancer-Research-Validates-Utility-of-Guardant-Reveal-Liquid-Biopsy-Test-for-Predicting-Recurrence-in-Colorectal-Cancer/default.aspx",
    "longitudinalSpecificity": 98.0,
    "longitudinalSpecificityCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-COSMOS-Study-Published-in-Clinical-Cancer-Research-Validates-Utility-of-Guardant-Reveal-Liquid-Biopsy-Test-for-Predicting-Recurrence-in-Colorectal-Cancer/default.aspx",
    "lod": "0.01% VAF",
    "lodCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-COSMOS-Study-Published-in-Clinical-Cancer-Research-Validates-Utility-of-Guardant-Reveal-Liquid-Biopsy-Test-for-Predicting-Recurrence-in-Colorectal-Cancer/default.aspx",
    "lodNotes": "Detection threshold approximately 0.01% VAF (~100 ppm); methylation-based detection (epiTF) enables tumor-naïve ctDNA detection at very low allele fractions.",
    "leadTimeVsImaging": 159.0,
    "leadTimeVsImagingCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-COSMOS-Study-Published-in-Clinical-Cancer-Research-Validates-Utility-of-Guardant-Reveal-Liquid-Biopsy-Test-for-Predicting-Recurrence-in-Colorectal-Cancer/default.aspx",
    "leadTimeVsImagingNotes": "CRC median 4.77 months from MRD+ to recurrence.",
    "requiresTumorTissue": null,
    "requiresTumorTissueNotes": "Plasma-only (tissue-free) MRD assay; tumor tissue is not required for panel design.",
    "requiresMatchedNormal": null,
    "requiresMatchedNormalNotes": "Does not require a matched-normal blood sample.",
    "initialTat": 7.0,
    "initialTatCitations": "https://www.guardanthealth.com/solutions/guardant-reveal/",
    "initialTatNotes": "Vendor-reported 7-day median TAT.",
    "followUpTat": 7.0,
    "followUpTatCitations": "https://www.guardanthealth.com/solutions/guardant-reveal/",
    "followUpTatNotes": "Vendor-reported 7-day median TAT.",
    "bloodVolume": 20.0,
    "bloodVolumeCitations": "https://www.guardanthealth.com/solutions/guardant-reveal/",
    "bloodVolumeNotes": "Commonly collected as two 10 mL Streck cfDNA tubes (≈20 mL).",
    "tat": 7.0,
    "tatCitations": "https://www.guardanthealth.com/solutions/guardant-reveal/",
    "tatNotes": "Guardant reports a typical ~7-day turnaround from sample receipt for Reveal.",
    "fdaStatus": "CLIA LDT; not FDA cleared/approved as of 2025.",
    "reimbursement": "Medicare (CRC only)",
    "reimbursementNote": "Medicare MolDX coverage for colorectal cancer MRD only - post-surgical and surveillance settings after curative-intent treatment. Not covered for other cancer types. Commercial coverage expanding via select BCBS plans.",
    "commercialPayers": ["BCBS Louisiana", "Geisinger Health Plan"],
    "commercialPayersCitations": "https://www.businesswire.com/news/home/20230720806084/en/Guardant-Health-receives-first-commercial-payor-coverage-for-Guardant-Reveal%E2%84%A2-test-from-Blue-Cross-and-Blue-Shield-of-Louisiana/",
    "commercialPayersNotes": "Blue Cross Blue Shield of Louisiana became first commercial payer to cover Guardant Reveal in July 2023. Geisinger Health Plan added coverage later in 2023. Additional BCBS plans (including BCBS Massachusetts) appear to have medical policies; verify with specific plan.",
    "cptCodes": "0569U (Guardant Reveal PLA code from mid-2025).",
    "cptCodesNotes": "Guardant Reveal PLA (2025).",
    "availableRegions": ["US"],
    "clinicalAvailability": "Clinical LDT – shipping",
    "exampleTestReport": "https://learn.colontown.org/wp-content/uploads/2022/01/Reveal-Sample-Report_postsurgery-positive-2-v2.pdf",
    "clinicalTrials": "NCCTG N0147 adjuvant FOLFOX trial (>2000; Guardant Reveal ctDNA analysis)",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical landmark assessment (63% sensitivity) and longitudinal surveillance (81% sensitivity) in CRC. Medicare coverage for both post-surgical and surveillance settings.",
    "totalParticipants": 2000,
    "numPublications": 10,
    "numPublicationsPlus": true
  },
  {
    "id": "mrd-7",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Commonly two Streck cfDNA tubes (~10 mL each) for monitoring; tissue + matched normal required at baseline",
    "sampleCitations": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/faq/",
    "name": "Signatera",
    "vendor": "Natera",
    "approach": "Tumor-informed",
    "method": "Tumor-informed, multiplex PCR–NGS ctDNA assay: tumor and matched-normal WES identify personal SNVs, and a 16-variant (or higher in newer versions) customized panel is tracked in serial plasma at high depth.",
    "cancerTypes": [
      "Colorectal",
      "Breast",
      "Bladder",
      "NSCLC",
      "Ovarian/Fallopian/Primary peritoneal",
      "Pan-solid ICI"
    ],
    "indicationsNotes": "Natera Signatera tumor-informed MRD assay with Medicare coverage for multiple solid-tumor indications: CRC (stage II–IV & oligometastatic, adjuvant & recurrence), breast cancer (neoadjuvant and stage IIb+ adjuvant & recurrence), bladder cancer (MIBC), NSCLC (stage I–III surveillance), and ovarian/fallopian/primary peritoneal cancer (adjuvant & recurrence), plus pan-solid tumor immune-checkpoint inhibitor (ICI) response monitoring.",
    "sensitivity": 94.0,
    "sensitivityCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "sensitivityNotes": "Recurrence Surveillance: CRC: 88-93% sens., 98% spec. Breast: 88-89% sens., 95-99% spec. Lung: 80-99% sens., 96-99% spec. Bladder: 99% sens., 98% spec. Ovarian: 99% sens.",
    "sensitivityStagesReported": "Stage II–IV combined (varies by cancer type)",
    "stageIISensitivity": null,
    "stageIISensitivityNotes": "CRC Stage II landmark ~65-73% in CIRCULATE-Japan; longitudinal higher. Stage II not separately reported for other cancer types. Stage-specific breakdowns would help inform treatment decisions.",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Stage III typically shows higher sensitivity than Stage II due to higher tumor burden; specific values combined with other stages in most publications.",
    "stageDataExpected": true,
    "specificity": 98.0,
    "specificityCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "specificityNotes": "Specificity ranges by cancer type: CRC 98%, Breast 95-99%, Lung 96-99%, Bladder 98%. Headline value of 98% reflects typical performance across indications.",
    "ppv": 98.0,
    "ppvCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "ppvNotes": "Overall PPV >98% (vendor, multi-tumor).",
    "npv": 96.0,
    "npvCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "npvNotes": "NSCLC distant/extracranial single timepoint NPV.",
    "landmarkSensitivity": 75.0,
    "landmarkSensitivityCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "landmarkSensitivityNotes": "NSCLC distant/extracranial single timepoint sensitivity.",
    "longitudinalSensitivity": 94.0,
    "longitudinalSensitivityCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "longitudinalSensitivityNotes": "NSCLC distant/extracranial longitudinal sensitivity.",
    "longitudinalSpecificity": 98.0,
    "longitudinalSpecificityCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "longitudinalSpecificityNotes": "Longitudinal specificity across cancer types ranges 96-99%; 98% represents typical performance.",
    "lod": "~0.01% VAF",
    "lodCitations": "https://www.natera.com/oncology/signatera-mrd-test/",
    "lodNotes": "Natera reports analytical sensitivity to ~0.01% tumor fraction with high specificity using integrated digital error suppression.",
    "leadTimeVsImaging": 300.0,
    "leadTimeVsImagingCitations": "https://investor.natera.com/news/news-details/2025/SignateraTM-Genome-Clinical-Performance-Highlighted-at-ASCO-2025/default.aspx",
    "leadTimeVsImagingNotes": "Ovarian ~10 months; NSCLC >7 months earlier than imaging.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Tumor-informed; needs primary tumor tissue.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "Matched normal blood required.",
    "variantsTracked": "16",
    "variantsTrackedNotes": "Original commercial design tracks 16 somatic variants per patient; some research/“Genome” configurations track more (e.g., 64) but 16 remains the standard clinical panel.",
    "variantsTrackedCitations": "https://www.natera.com/oncology/signatera-mrd-test/",
    "initialTat": 28.0,
    "initialTatNotes": "Baseline tumor/normal sequencing and panel design typically require ~3–4 weeks.",
    "initialTatCitations": "https://www.natera.com/oncology/signatera-mrd-test/",
    "followUpTat": 9.0,
    "followUpTatNotes": "Longitudinal MRD blood draws generally reported within ~7–10 days.",
    "followUpTatCitations": "https://www.natera.com/oncology/signatera-mrd-test/",
    "bloodVolume": 20.0,
    "bloodVolumeNotes": "Commonly two Streck cfDNA tubes (~10 mL each) for monitoring; tissue + matched normal required at baseline",
    "bloodVolumeCitations": "https://www.natera.com/oncology/signatera-mrd-test/",
    "tat": 28.0,
    "tatCitations": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/faq/",
    "tatNotes": "Overall paradigm: ~4 weeks for initial build, ~1–1.5 weeks for follow-up tests.",
    "fdaStatus": "CLIA LDT; not FDA-cleared/approved as of late 2025 (clinical validation via numerous peer-reviewed studies).",
    "reimbursement": "Medicare (CRC, Breast, Bladder, NSCLC, Ovarian, ICI)",
    "reimbursementNote": "Medicare MolDX coverage for: CRC (stage II-IV, oligometastatic), breast cancer (neoadjuvant, stage IIb+ adjuvant/recurrence), bladder (MIBC), NSCLC (stage I-III surveillance), ovarian/fallopian/peritoneal, and pan-solid ICI response monitoring. ADLT pricing. Coverage varies by indication - verify specific cancer type with payer.",
    "commercialPayers": ["UnitedHealthcare", "Cigna", "Anthem BCBS", "BCBS Louisiana", "Blue Shield of California"],
    "commercialPayersCitations": "https://www.natera.com/oncology/billing/",
    "commercialPayersNotes": "Natera is in-network with most major health plans including Cigna, UnitedHealthcare, and Blue Shield of California. BCBS Louisiana provides explicit coverage. Note: Aetna lists Signatera codes as in-network but current policies show non-covered; verify with plan.",
    "cptCodes": "0340U (ADLT)",
    "cptCodesNotes": "Signatera PLA (ADLT pricing).",
    "codeType": "PLA",
    "medicareRate": 3500,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "availableRegions": ["US", "EU", "UK", "International"],
    "clinicalAvailability": "Clinical LDT – shipping",
    "independentValidation": "Yes",
    "independentValidationNotes": "Multiple peer-reviewed and prospective studies across tumors.",
    "exampleTestReport": "https://www.natera.com/resource-library/signatera/signatera-patient-test-sample-report/",
    "clinicalTrials": "BESPOKE CRC (NCT04264702); multicentre prospective observational study of ~2,000 stage I–IV colorectal cancer patients at up to 200 U.S. sites (MRD and surveillance cohorts)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04264702",
    "clinicalSettings": ["Neoadjuvant", "Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Most broadly validated across clinical settings. Neoadjuvant: breast cancer (I-SPY2 trial, Medicare covered). Post-surgery: landmark ~4 weeks (75% NSCLC sens). Post-adjuvant: after chemo completion. Surveillance: longitudinal monitoring (94% NSCLC sens). Medicare covers all settings for CRC, breast, bladder, NSCLC, ovarian.",
    "totalParticipants": 2000,
    "totalParticipantsCitations": "https://clinicaltrials.gov/study/NCT04264702",
    "numPublications": 100,
    "numPublicationsCitations": "https://www.natera.com/company/news/natera-announces-publication-of-over-100-peer-reviewed-papers-on-signateratm/",
    "numPublicationsPlus": true,
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Colon Cancer, Rectal Cancer, Merkel Cell Carcinoma V.2.2025",
    "nccnGuidelinesNotes": "NCCN V.2.2025 update specifically references Signatera publications. CRC: ctDNA included as high risk factor for recurrence. MCC: positive recommendation for ctDNA monitoring in surveillance, citing Signatera data.",
    "nccnGuidelinesCitations": "https://www.natera.com/company/news/nccn-strengthens-guidance-on-ctdna-in-colon-cancer-rectal-cancer-and-merkel-cell-carcinoma/"
  },
  {
    "id": "mrd-8",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 17,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "RUO specimen overview describes two 8.5 mL Streck cfDNA tubes (~17 mL total) per timepoint.",
    "sampleCitations": "https://www.tempus.com/wp-content/uploads/2024/01/Tempus-LS_xM-RUO-Overview.pdf",
    "name": "Tempus xM MRD",
    "vendor": "Tempus",
    "approach": "Tumor-naïve",
    "method": "Tumor-naïve MRD assay that combines variant-based ctDNA detection with methylation/fragmentomics signals in a dual-workflow, blood-only design; current clinical positioning focuses on colorectal cancer.",
    "cancerTypes": [
      "Colorectal"
    ],
    "indicationsNotes": "Tempus xM tumor-naïve MRD assay currently marketed for colorectal cancer, with coverage and data focused on CRC; separate Tempus xM (NeXT Personal Dx) tumor-informed offering for solid tumors, including breast.",
    "sensitivity": 61.1,
    "sensitivityNotes": "Landmark sensitivity 61.1% from GALAXY (CIRCULATE-Japan) 80-patient CRC subset. Longitudinal sensitivity 83.3%. Headline uses landmark value.",
    "sensitivityCitations": "https://www.businesswire.com/news/home/20240515005320/en/",
    "specificity": 94.0,
    "specificityCitations": "https://www.businesswire.com/news/home/20240515005320/en/",
    "specificityNotes": "Landmark specificity 94% from GALAXY subset. Longitudinal specificity 89.5%.",
    "landmarkSensitivity": 61.1,
    "landmarkSensitivityNotes": "CRC landmark sensitivity from GALAXY (CIRCULATE-Japan) subset analysis of 80 resected stage II-III colorectal cancer patients.",
    "landmarkSensitivityCitations": "https://www.businesswire.com/news/home/20240515005320/en/ | Tempus BusinessWire press release May 2024",
    "landmarkSpecificity": 94.0,
    "landmarkSpecificityNotes": "CRC landmark specificity from GALAXY (CIRCULATE-Japan) subset analysis.",
    "landmarkSpecificityCitations": "https://www.businesswire.com/news/home/20240515005320/en/ | Tempus BusinessWire press release May 2024",
    "longitudinalSensitivity": 83.3,
    "longitudinalSensitivityCitations": "https://www.businesswire.com/news/home/20240531484360/en/Tempus-Announces-the-Clinical-Launch-of-its-MRD-Testing-Portfolio",
    "longitudinalSpecificity": 89.5,
    "longitudinalSpecificityCitations": "https://www.businesswire.com/news/home/20240531484360/en/Tempus-Announces-the-Clinical-Launch-of-its-MRD-Testing-Portfolio",
    "lod": "0.01% VAF",
    "lodCitations": "https://www.businesswire.com/news/home/20240531484360/en/Tempus-Announces-the-Clinical-Launch-of-its-MRD-Testing-Portfolio",
    "lodNotes": "Detection threshold approximately 0.01% VAF based on GALAXY/CIRCULATE-Japan trial performance.",
    "requiresTumorTissue": null,
    "requiresMatchedNormal": null,
    "initialTat": 12,
    "initialTatCitations": "https://www.tempus.com/oncology/genomic-profiling/xm/",
    "initialTatNotes": "10-14 days TAT; tumor-naïve design enables faster turnaround than tissue-dependent assays.",
    "followUpTatNotes": "Public materials emphasize rapid repeat testing from blood-only workflows; specific day counts vary by context and are not standardized in a single published metric.",
    "bloodVolume": 17.0,
    "bloodVolumeCitations": "https://www.tempus.com/wp-content/uploads/2024/01/Tempus-LS_xM-RUO-Overview.pdf",
    "bloodVolumeNotes": "RUO specimen overview describes two 8.5 mL Streck cfDNA tubes (~17 mL total) per timepoint.",
    "tatNotes": "Overall TAT is marketed as faster than tumor-informed assays due to avoiding tissue sequencing, but a precise canonical value is not available.",
    "fdaStatus": "CLIA LDT (for clinical xM portfolio) with RUO offering for biopharma; not FDA cleared/approved as of 2025.",
    "reimbursement": "Coverage emerging; verify payer-specific policies.",
    "reimbursementNote": "xM MRD is newer than some competitors; commercial and Medicare coverage are evolving and may currently be more limited than for Signatera or Guardant Reveal.",
    "cptCodes": "Contact vendor for current billing guidance.",
    "clinicalAvailability": "Clinical LDT – shipping for colorectal cancer; RUO version also available via Tempus Life Sciences.",
    "clinicalTrials": "GALAXY (CIRCULATE-Japan) subset analysis; 80 resected stage II–III colorectal cancer patients randomly selected and enriched for recurrence; Tempus xM tumor-naïve MRD assay with methylation + variant classifiers",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical landmark (61% sens, 94% spec) and longitudinal surveillance (83% sens, 90% spec) in CRC via GALAXY/CIRCULATE-Japan.",
    "totalParticipants": 80,
    "numPublications": 3,
    "numPublicationsPlus": true
  },
  {
    "id": "mrd-9",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Two 10 mL Streck blood collection tubes (BCT) for plasma and buffy coat at the landmark time point; plasma-only draws (Streck tubes) for longitudinal monitoring.",
    "sampleCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "name": "Labcorp Plasma Detect",
    "vendor": "Labcorp",
    "approach": "Tumor-informed",
    "method": "Tumor-informed whole-genome sequencing (WGS) ctDNA MRD assay: WGS of tumor tissue, buffy coat (germline) and plasma at a landmark time point is used with a proprietary machine-learning pipeline to identify thousands of high-confidence, patient-specific somatic variants (median ~5000 SNVs), which are then tracked longitudinally in cell-free DNA without bespoke panel design.",
    "cancerTypes": [
      "Colon cancer (Stage III)",
      "Lung cancer (in validation)",
      "Bladder cancer (in validation)",
      "Multi-solid (expanding)"
    ],
    "indicationsNotes": "Labcorp Plasma Detect WGS-based MRD assay. Clinically validated for post-surgery and post-adjuvant MRD assessment in stage III colon cancer (PROVENC3); clinical use launched April 2025 via Early Experience Program. Expanding to additional solid tumors including lung and bladder cancer.",
    "sensitivity": 95,
    "sensitivityNotes": "Clinical sensitivity ~95% in PROVENC3 stage III colon cancer validation; analytical sensitivity characterized via WGS of thousands of tumor-specific variants.",
    "sensitivityCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect | https://www.nature.com/articles/s41591-024-03078-8",
    "specificity": 99.4,
    "specificityCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "specificityNotes": "Analytical specificity ~99.4% for ctDNA-negative reference specimens in internal validation; clinical specificity for recurrence is still being characterized (PROVENC3 and related studies).",
    "lod": "10 ppm (LOD50)",
    "lod95": "50 ppm (0.005%)",
    "lod95Citations": "https://www.prnewswire.com/news-releases/labcorp-launches-molecular-residual-disease-and-liquid-biopsy-solutions-302435767.html | https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "lodCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect | https://www.prnewswire.com/news-releases/labcorp-launches-molecular-residual-disease-and-liquid-biopsy-solutions-302435767.html",
    "lodNotes": "LOD95 of 0.005% (50 ppm) per Labcorp official specifications. LOD50 ≈ 0.001% (10 ppm). WGS approach tracks thousands of tumor-specific variants (vs 18-50 for WES-based approaches), enabling improved sensitivity at low ctDNA levels.",
    "leadTimeVsImaging": null,
    "leadTimeVsImagingCitations": "Labcorp press releases Nov 2025.",
    "leadTimeVsImagingNotes": "Detects disease progression up to 18 months earlier than standard clinical measures (median 2.3 months lead time in chemotherapy monitoring study).",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires FFPE tumor tissue at the landmark time point for WGS to define the tumor-informed MRD signature plus buffy coat for germline/CHIP filtering.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "Uses buffy coat (PBMC) germline DNA to filter germline and non–tumor-specific variants; germline input is required for assay design.",
    "variantsTracked": "5000",
    "variantsTrackedCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "variantsTrackedNotes": "Median of ~5000 high-confidence tumor-specific single nucleotide variants (SNVs) per patient in the MRD signature, tracked longitudinally. No bespoke panel manufacturing required.",
    "initialTat": 14.0,
    "initialTatCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "initialTatNotes": "Landmark ctDNA MRD result available in as few as 14 days from sample receipt. Standardized WGS workflow eliminates custom reagent delays.",
    "followUpTat": 7.0,
    "followUpTatCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "followUpTatNotes": "Longitudinal surveillance time points reported in as few as 7 days from sample receipt.",
    "bloodVolume": 20.0,
    "bloodVolumeCitations": "https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "bloodVolumeNotes": "Two 10 mL Streck blood collection tubes (BCT) for plasma and buffy coat at the landmark time point; plasma-only draws (Streck tubes) for longitudinal monitoring.",
    "tat": 14.0,
    "tatCitations": "https://clpmag.com/disease-states/cancer/labcorp-plasma-detect-and-pgdx-elio-plasma-focus-dx-launched/ | https://oncology.labcorp.com/biopharma-partners/plasma-detect",
    "tatNotes": "Landmark (initial) MRD result in as few as 14 days and longitudinal MRD results in as few as 7 days from sample receipt (Plasma Detect assay specifications).",
    "fdaStatus": "CLIA LDT",
    "fdaStatusCitations": "Labcorp press release April 2025.",
    "reimbursement": "Coverage emerging",
    "reimbursementNote": "Clinical use launched April 2025 for stage III colon cancer via Early Experience Program. Reimbursement pathways in development. No public Medicare LCD or dedicated PLA code as of 2025.",
    "cptCodesNotes": "No public PLA/CPT code specific to Labcorp Plasma Detect as of 2025; contact Labcorp for current billing guidance.",
    "clinicalAvailability": "Clinical LDT – Early Experience Program (stage III colon cancer); Research Use for other indications",
    "independentValidation": "Yes",
    "independentValidationNotes": "Clinically validated in the PROVENC3 stage III colon cancer cohort (AACR 2024) and related ASCO/ESMO presentations assessing post-surgery and post-adjuvant ctDNA status and recurrence risk.",
    "clinicalTrials": "PROVENC3 (colon cancer validation with NKI); MEDOCC-CrEATE (stage II colon ACT); 10+ additional clinical studies in US and internationally",
    "clinicalTrialsCitations": "Labcorp press releases; Nature Medicine 2025; Clinical Cancer Research 2025.",
    "clinicalSettings": ["Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated in PROVENC3 for post-surgical and post-adjuvant ctDNA assessment in stage III colon cancer. Longitudinal surveillance also validated.",
    "totalParticipants": 236,
    "totalParticipantsNotes": "236 patients in PROVENC3; currently evaluated in 10+ clinical studies across multiple cancer types.",
    "numPublications": 2,
    "numPublicationsCitations": "Nature Medicine 2025 (mesothelioma); Clinical Cancer Research 2025 (head and neck).",
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "Developed under PGDx quality management system and design control. Clinical use for stage III colon cancer; research use for other solid tumors. Expanding indications expected."
  },
  {
    "id": "mrd-10",
    "sampleCategory": "Blood/Plasma",
    "sampleCollectionNotes": "Foundation does not publish a fixed blood volume; typical mPCR ctDNA workflows use two Streck tubes (~20 mL whole blood).",
    "name": "FoundationOne Tracker (MRD)",
    "vendor": "Foundation Medicine / Natera",
    "approach": "Tumor-informed",
    "method": "Personalized ctDNA assay derived from FoundationOne CDx tumor sequencing; uses 2-16 patient-specific somatic variants to detect and quantify mean tumor molecules per mL (MTM/mL) in serial plasma samples via multiplex PCR workflow.",
    "cancerTypes": [
      "Multi-solid tumors"
    ],
    "indicationsNotes": "Tissue-informed ctDNA MRD assay for early- and late-stage solid tumors. Uses archival or new tumor tissue profiled by FoundationOne CDx to build a patient-specific panel, then quantifies MTM/mL in serial plasma samples for MRD detection and surveillance after curative-intent therapy. Note: The TRM application has separate clinical availability with Medicare coverage; the MRD application remains investigational.",
    "sensitivity": 100,
    "sensitivityCitations": "Zollinger DR et al. PLoS One 2024;19:e0302129; IMpower131 trial data (Kasi PM et al. Clin Cancer Res 2023).",
    "sensitivityNotes": "100% analytical sensitivity in dilution series at ≥5 MTM/mL when at least two tumor variants are monitored (>97.3% at lower levels). ⚠️ Analytical validation (dilution series); clinical MRD sensitivity is indication- and timepoint-specific.",
    "analyticalValidationWarning": true,
    "validationCohortStudy": "Zollinger DR et al. PLoS One 2024 (analytical validation)",
    "specificity": 99.6,
    "specificityCitations": "Zollinger DR et al. PLoS One 2024;19:e0302129.",
    "specificityNotes": "Sample-level analytical specificity was 99.6% in contrived and clinical samples.",
    "lod": "0.01% VAF",
    "lodCitations": "Zollinger DR et al. PLoS One 2024;19:e0302129.",
    "lodNotes": "Detection threshold approximately 0.01% VAF; performance reported in MTM/mL units with analytical sensitivity ≥5 MTM/mL with ≥2 variants monitored.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires prior or concurrent tumor CGP by FoundationOne CDx to identify 2-16 patient-specific somatic variants for personalized panel design.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Germline and CHIP filtering performed computationally without mandatory matched-normal sequencing.",
    "initialTat": 8,
    "initialTatCitations": "Foundation Medicine website; Zollinger DR et al. PLoS One 2024.",
    "initialTatNotes": "7-10 days from sample receipt and variant design to result; initial result requires completed FoundationOne CDx.",
    "followUpTat": null,
    "followUpTatNotes": "Serial MRD timepoints reuse the established patient-specific panel with similar turnaround.",
    "bloodVolume": null,
    "bloodVolumeNotes": "Foundation does not publish a fixed blood volume; typical mPCR ctDNA workflows use two Streck tubes (~20 mL whole blood).",
    "fdaStatus": "FDA Breakthrough Device designation (Feb 2022) for MRD detection in early-stage solid tumors; investigational/early access assay – NOT yet FDA cleared.",
    "fdaStatusCitations": "Foundation Medicine press release, February 3, 2022.",
    "reimbursement": "Not applicable",
    "reimbursementNote": "MRD applications are investigational; not routinely billed to payers. Note: TRM use has separate Medicare coverage (see TRM category).",
    "cptCodesNotes": "None for MRD investigational use.",
    "availableRegions": ["US", "EU", "International"],
    "availableRegionsNotes": "Investigational use available via Foundation Medicine and Roche global network for biopharma collaborations.",
    "clinicalAvailability": "Investigational / early access program via Foundation Medicine for MRD applications; biopharma and academic collaborations globally.",
    "clinicalTrials": "Used in translational and interventional cohorts for MRD (e.g., early bladder cancer post-cystectomy, stage II/III CRC) correlating ctDNA dynamics with outcomes.",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Investigational MRD application validated in post-surgical and surveillance settings across multiple solid tumors. FDA Breakthrough Device designation for MRD detection.",
    "totalParticipants": null,
    "numPublications": 3,
    "numPublicationsPlus": true,
    "isRUO": false,
    "isInvestigational": true,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "Holds FDA Breakthrough Device designation for MRD but is not yet FDA cleared. The underlying assay platform is a clinical LDT (same technology as FoundationOne Tracker TRM which has Medicare coverage), but MRD-specific applications remain investigational."
  },
  {
    "id": "mrd-11",
    "sampleCategory": "Blood/Plasma",
    "sampleCollectionNotes": "Standard ctDNA plasma volumes; explicit whole-blood volume not specified publicly.",
    "name": "Foundation TI-WGS MRD (RUO)",
    "vendor": "Foundation Medicine",
    "approach": "Tumor-informed",
    "method": "Tissue-informed whole-genome sequencing MRD assay; WGS of tumor tissue and longitudinal plasma combined with a proprietary bioinformatics algorithm to detect and quantify ctDNA tumor fraction by monitoring hundreds to thousands of tumor-specific variants.",
    "cancerTypes": [
      "Multi-solid tumors"
    ],
    "indicationsNotes": "Sensitive MRD assay offered for research use in early- and late-stage solid tumors. Available through Foundation's FlexOMx Lab for drug-development studies requiring deep ctDNA detection (e.g., early-stage or low-shedding cancers).",
    "sensitivity": 90,
    "sensitivityCitations": "Foundation Medicine press release, September 23, 2025; https://www.foundationmedicine.com/monitoring-portfolio",
    "sensitivityNotes": "90% analytical sensitivity at 10 ppm tumor fraction threshold in feasibility studies; cross-indication sensitivity values are study-specific.",
    "specificity": 100,
    "specificityCitations": "Foundation Medicine Monitoring Portfolio technical specifications.",
    "specificityNotes": "100% analytical specificity reported in feasibility data. ⚠️ Feasibility data only; clinical specificity study- and tumor-specific.",
    "analyticalValidationWarning": true,
    "validationCohortStudy": "Foundation Medicine feasibility studies (RUO)",
    "lod": "10 ppm (≈0.001%)",
    "lodCitations": "https://www.foundationmedicine.com/monitoring-portfolio",
    "lodNotes": "Reported to detect ctDNA tumor fraction down to 10 ppm in both early- and late-stage cancer.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires WGS of tumor tissue to build the patient-specific genomic signature; typically uses the same FFPE block as FoundationOne CDx.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Product highlights emphasize that matched-normal samples are NOT required for CHIP/germline filtering.",
    "initialTat": 14,
    "initialTatCitations": "Foundation Medicine FlexOMx Lab specifications.",
    "initialTatNotes": "Approximately 14 days TAT; depends on WGS depth and study design.",
    "followUpTat": null,
    "followUpTatNotes": "Follow-up draws reuse the existing tumor-informed signature; timelines negotiated at study level.",
    "bloodVolume": null,
    "bloodVolumeNotes": "Standard ctDNA plasma volumes; explicit whole-blood volume not specified publicly.",
    "fdaStatus": "Research Use Only (RUO) – CLIA-certified, CAP-accredited FlexOMx Lab; NOT FDA cleared.",
    "fdaStatusCitations": "Foundation Medicine press release, September 23, 2025.",
    "fdaStatusNotes": "RUO assay for biopharma research partnerships only. Not available for clinical ordering. Foundation Medicine has not announced plans for FDA clearance or clinical LDT launch.",
    "reimbursement": "Not applicable",
    "reimbursementNote": "RUO only; costs are sponsor-funded in research/clinical-development collaborations.",
    "cptCodesNotes": "None (RUO research assay).",
    "availableRegions": ["US", "EU", "International"],
    "availableRegionsNotes": "RUO available globally via Foundation's FlexOMx Lab for biopharma and academic partnerships.",
    "clinicalAvailability": "Available globally to biopharma and academic partners as a central-lab RUO MRD solution via Foundation's FlexOMx Lab. Launched September 2025.",
    "clinicalTrials": "Positioned for MRD assessment and ctDNA kinetics in oncology drug-development studies, particularly early-stage or low-shed settings.",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "RUO platform for research use in post-surgical MRD assessment and longitudinal surveillance, particularly in early-stage or low-shedding tumors.",
    "totalParticipants": null,
    "numPublications": 0,
    "numPublicationsPlus": false,
    "isRUO": true,
    "isInvestigational": false,
    "isClinicalLDT": false,
    "regulatoryStatusNotes": "Research Use Only assay launched September 2025 through FlexOMx Lab; offered for retrospective clinical trials and research studies, not for diagnostic use."
  },
  {
    "id": "mrd-12",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 4,
    "sampleTubeCount": 1,
    "sampleCollectionNotes": "Requires less than one tube of blood (as little as 3-4 mL blood or 1-2 mL plasma).",
    "sampleCitations": "https://www.guardanthealth.com/",
    "name": "Veracyte MRD (C2i Genomics platform)",
    "vendor": "Veracyte (C2i Genomics)",
    "approach": "Tumor-informed",
    "method": "Whole-genome sequencing (WGS) of tumor tissue and germline DNA combined with AI-driven pattern recognition to create patient-specific ctDNA signatures; subsequent blood samples are analyzed via WGS and AI to detect residual cancer.",
    "cancerTypes": [
      "Muscle-invasive bladder cancer (first indication)",
      "Multi-solid (planned expansion)"
    ],
    "indicationsNotes": "WGS-based MRD testing platform acquired by Veracyte from C2i Genomics in February 2024. First clinical test planned for muscle-invasive bladder cancer (MIBC) with launch expected H1 2026.",
    "sensitivity": 91,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/36270894/ | Nordentoft I et al. Eur Urol 2023; EAU25 Abstract A0162",
    "sensitivityNotes": "Prior publication showed 91% sensitivity at 92% specificity in urothelial carcinoma. TOMBOLA trial data presented at EAU25 demonstrated higher accuracy than ddPCR.",
    "specificity": 88,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/36270894/ | EAU25 presentation, TOMBOLA trial (Abstract A0162)",
    "specificityNotes": "TOMBOLA trial showed 88% specificity at 6-month milestone vs 62% for ddPCR; detected recurrence 93 days earlier than imaging.",
    "lod": "0.001% TF",
    "lodCitations": "Veracyte investor communications; C2i Genomics technical specifications.",
    "lodNotes": "Detection threshold approximately 0.001% tumor fraction (10 ppm) via WGS-based approach.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires WGS of tumor tissue and germline DNA to establish patient-specific signature.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "WGS of germline (non-tumor) DNA is part of the workflow to distinguish somatic from germline variants.",
    "initialTat": 14,
    "initialTatNotes": "Sample to result in approximately 2 weeks per acquisition announcement.",
    "followUpTat": 14,
    "followUpTatNotes": "Follow-up samples analyzed via WGS with similar turnaround.",
    "bloodVolume": 4,
    "bloodVolumeCitations": "GEN Edge January 2024; C2i acquisition announcement.",
    "bloodVolumeNotes": "Requires less than one tube of blood (as little as 3-4 mL blood or 1-2 mL plasma).",
    "fdaStatus": "Pre-commercial research platform; NOT FDA cleared. First clinical test (MIBC) expected H1 2026.",
    "fdaStatusNotes": "Pre-commercial research platform acquired from C2i Genomics in Feb 2024. Clinical launch for muscle-invasive bladder cancer planned H1 2026. Not yet available for clinical ordering.",
    "fdaStatusCitations": "Veracyte Q1 2025 earnings; GenomeWeb May 2025; EAU25 presentation.",
    "reimbursement": "Not applicable",
    "reimbursementNote": "Pre-commercial; Veracyte plans to leverage established urology channel for MIBC indication.",
    "cptCodesNotes": "None (pre-commercial).",
    "clinicalAvailability": "Pre-commercial research platform. Clinical launch planned H1 2026 for muscle-invasive bladder cancer.",
    "clinicalTrials": "TOMBOLA trial (NCT04138628) – multicenter interventional in MIBC (100 patients); UMBRELLA trial (enrolled Q1 2025) for pancreatic cancer, sarcoma, CRC, NSCLC.",
    "clinicalTrialsCitations": "Veracyte Q1 2025 earnings; EAU25 presentation.",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "TOMBOLA trial validates post-surgical and surveillance MRD in muscle-invasive bladder cancer. Detected recurrence 93 days earlier than imaging.",
    "totalParticipants": 100,
    "numPublications": 2,
    "numPublicationsPlus": true,
    "isRUO": true,
    "isInvestigational": true,
    "isClinicalLDT": false,
    "regulatoryStatusNotes": "Pre-commercial investigational WGS-based MRD platform acquired by Veracyte (Feb 2024, $70M + $25M milestones). TOMBOLA trial supports validation. First clinical test for MIBC expected H1 2026."
  },
  {
    "id": "mrd-13",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 4,
    "sampleTubeCount": 1,
    "sampleCollectionNotes": "CRC MRD study used median 4 mL plasma (range 1-4 mL).",
    "sampleCitations": "https://www.guardanthealth.com/",
    "name": "Guardant LUNAR (RUO platform)",
    "vendor": "Guardant Health",
    "approach": "Tumor-naïve",
    "method": "Plasma-only ctDNA assay integrating genomic alterations (SNVs, indels) with epigenomic cancer signatures (aberrant DNA methylation) to detect MRD without requiring tumor tissue sequencing. Originally called LUNAR-1.",
    "cancerTypes": [
      "Colorectal cancer (primary validation)",
      "Multi-solid (research)"
    ],
    "indicationsNotes": "Research platform that evolved into the clinical Guardant Reveal LDT. Designed to detect MRD without prior knowledge of patient's tumor mutations by combining genomic and methylation signatures.",
    "sensitivity": 56,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/ | Parikh AR et al. Clin Cancer Res 2021;27:5586-5594",
    "sensitivityNotes": "In CRC cohort (n=84 evaluable): landmark sensitivity 56% (1 month post-therapy), longitudinal sensitivity 69%. Integrating epigenomic analysis enhanced sensitivity by 25-36%.",
    "specificity": 100,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/ | Parikh AR et al. Clin Cancer Res 2021;27:5586-5594",
    "specificityNotes": "Landmark specificity ~100% with 100% PPV (all 15 patients with detectable ctDNA recurred); longitudinal specificity ~91%. ⚠️ 100% PPV from very small subset (n=15).",
    "smallSampleWarning": true,
    "validationCohortSize": 103,
    "validationCohortStudy": "Parikh AR et al. Clin Cancer Res 2021 (n=103 total, n=84 evaluable, n=15 ctDNA+)",
    "lod": "0.01% VAF",
    "lodCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/ | Parikh AR et al. Clin Cancer Res 2021",
    "lodNotes": "Detection threshold approximately 0.01% allele frequency; combines genomic alterations with epigenomic methylation signatures.",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Explicitly designed as plasma-only assay, not requiring sequencing of tumor tissue – a key differentiator from tissue-informed approaches.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Plasma-only assay uses integrated genomic and epigenomic signatures without matched-normal sequencing; filters CHIP variants computationally.",
    "initialTat": 10,
    "initialTatCitations": "https://guardanthealth.com/solutions/guardant-reveal/",
    "initialTatNotes": "7-10 days TAT; research platform TAT was study-specific but clinical derivative (Guardant Reveal) reports similar turnaround.",
    "followUpTat": null,
    "followUpTatNotes": "Follow-up draws processed via same plasma-only workflow.",
    "bloodVolume": 4,
    "bloodVolumeCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/ | Parikh AR et al. Clin Cancer Res 2021",
    "bloodVolumeNotes": "CRC MRD study used median 4 mL plasma (range 1-4 mL).",
    "fdaStatus": "Research-use-only MRD platform; clinical implementation transitioned to Guardant Reveal LDT.",
    "fdaStatusNotes": "RUO research platform (formerly LUNAR-1). Clinical implementation has transitioned to Guardant Reveal, which is available as a clinical LDT. LUNAR platform retained for research collaborations.",
    "fdaStatusCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/ | Parikh AR et al. Clin Cancer Res 2021; https://guardanthealth.com/ | Guardant Health website",
    "reimbursement": "Not applicable",
    "reimbursementNote": "RUO platform; costs study-funded. Clinical product Guardant Reveal has separate reimbursement pathway.",
    "cptCodesNotes": "None (research platform; Guardant Reveal is the clinical LDT).",
    "clinicalAvailability": "Available to academic and biopharma partners as research platform. Guardant Reveal is the clinical LDT derived from this technology.",
    "clinicalTrials": "CRC MRD study at Massachusetts General (Parikh et al. 2021, n=103); COSMOS study; PEGASUS trial; COBRA trial.",
    "clinicalTrialsCitations": "https://pubmed.ncbi.nlm.nih.gov/33926918/ | Parikh AR et al. Clin Cancer Res 2021;27:5586-5594",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "RUO platform validated for post-therapy landmark (56% sens at 1 month) and longitudinal surveillance (69% sens) in CRC.",
    "totalParticipants": 103,
    "numPublications": 5,
    "numPublicationsPlus": true,
    "isRUO": true,
    "isInvestigational": false,
    "isClinicalLDT": false,
    "regulatoryStatusNotes": "Research/development platform (originally LUNAR-1); the patient-facing MRD offering is Guardant Reveal (tracked separately as CLIA LDT). Demonstrated feasibility of tumor-uninformed plasma-only MRD detection."
  },
  {
    "id": "mrd-14",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 1,
    "sampleCollectionNotes": "One 10-mL Streck tube of whole blood required.",
    "sampleCitations": "https://www.biodesix.com/",
    "name": "NavDx",
    "vendor": "Naveris",
    "approach": "Tumor-naïve",
    "method": "Proprietary quantitative digital droplet PCR assay detecting tumor tissue modified viral (TTMV)-HPV DNA fragments in plasma; detects HPV genotypes 16, 18, 31, 33, and 35; reports TTMV Score (normalized TTMV-HPV DNA fragments/mL plasma).",
    "cancerTypes": [
      "HPV+ oropharyngeal (head & neck) cancer",
      "Anal squamous cell carcinoma (ASCC)",
      "HPV-driven gynecologic cancers (via NavDx+Gyn)"
    ],
    "indicationsNotes": "First and only clinically validated circulating TTMV-HPV DNA blood test. Detects MRD and recurrence in HPV-driven cancers before clinical or radiographic evidence. Used across the care continuum: pre-treatment baseline, treatment response assessment, post-treatment MRD surveillance, and recurrence detection.",
    "leadTimeVsImaging": 120,
    "leadTimeVsImagingCitations": "https://pubmed.ncbi.nlm.nih.gov/32017652/ | Chera BS et al. J Clin Oncol 2020;38:1050-1058",
    "leadTimeVsImagingNotes": "Median ~4 months (~120 days) lead time vs imaging for recurrence detection in HPV-driven oropharyngeal cancer surveillance cohorts.",
    "sensitivity": 90.4,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37422913/ | Ferrandino RN et al. JAMA Otolaryngol 2023; https://pubmed.ncbi.nlm.nih.gov/37566241/ | Hanna GJ et al. Clin Cancer Res 2023",
    "sensitivityNotes": "Clinical sensitivity 90.4% for recurrent HPV-associated OPSCC; 91.5% for pre-treatment diagnosis; 79.2-89% for surveillance depending on timepoint. For ASCC, multi-center study showed high accuracy.",
    "specificity": 98.6,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/37422913/ | Ferrandino RN et al. JAMA Otolaryngol 2023; https://pubmed.ncbi.nlm.nih.gov/37566241/ | Hanna GJ et al. Clin Cancer Res 2023",
    "specificityNotes": "Clinical specificity 98.6% for OPSCC; 97-100% in surveillance cohorts. Reliably distinguishes TTMV-HPV DNA from non-cancerous HPV DNA sources.",
    "ppv": 98,
    "ppvCitations": "https://navdx.com/physician-faqs",
    "ppvNotes": "Per-test PPV of 98% for ASCC; 97.9% for OPSCC. ≥95% PPV for cancer recurrence when patients had at least one positive test result.",
    "npv": 95,
    "npvCitations": "https://navdx.com/physician-faqs",
    "npvNotes": "Per-test NPV of 95% for ASCC; 95.7-98% for OPSCC surveillance. ≥98% of patients whose TTMV Score remained negative had no recurrence.",
    "lod": "0-1.10 copies/µL",
    "lodCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9955790/ | Diagnostics 2023;13:725",
    "lodNotes": "Analytical LOD: 0-1.10 copies/μL across HPV types 16, 18, 31, 33, 35. LOQ: <1.20-4.11 copies/μL. LOB: 0-0.32 copies/μL. Per analytical validation paper in Diagnostics (PMC9955790).",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Tumor-naïve approach; does not require prior tumor sequencing. Detects HPV-derived ctDNA directly without need for patient-specific panel design. For patients without pre-treatment NavDx, primary tumor tissue may be tested to confirm HPV genotype.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "No matched normal required; TTMV-HPV DNA biomarker is tumor-specific by nature.",
    "initialTat": 7,
    "initialTatNotes": "Reports issued within 7 calendar days from sample receipt per Naveris physician ordering information. No baseline panel design required (tumor-naïve approach).",
    "followUpTat": 7,
    "followUpTatNotes": "Serial monitoring uses same 7-day TAT; consistent turnaround for all tests.",
    "tat": "7 days",
    "tatCitations": "https://naveris.com/physicians/",
    "bloodVolume": 10,
    "bloodVolumeCitations": "NavDx physician ordering information.",
    "bloodVolumeNotes": "One 10-mL Streck tube of whole blood required.",
    "fdaStatus": "Clinical LDT – CLIA high-complexity test; CAP and NYSDOH accredited; NOT FDA cleared",
    "fdaStatusCitations": "Naveris website; Diagnostics 2023;13:725.",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage via Palmetto GBA MolDX: HPV+ oropharyngeal cancer (Nov 2023), anal squamous cell carcinoma (Nov 2025). CMS ADLT designation effective April 2024.",
    "commercialPayers": ["Highmark", "Blue Shield of California"],
    "commercialPayersCitations": "Naveris press releases Feb 2024, July 2024.",
    "commercialPayersNotes": "Highmark coverage announced Feb 2024; Blue Shield of California coverage effective July 1, 2024.",
    "cptCodes": "0356U",
    "cptCodesNotes": "CPT 0356U for TTMV-HPV DNA testing; ADLT status effective April 1, 2024.",
    "codeType": "PLA",
    "medicareRate": 1800,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "clinicalAvailability": "Commercially available in US. Integrated into clinical practice by >1,000 healthcare providers at >400 medical sites. ~100,000 patient-physician encounters.",
    "clinicalTrials": "Phase II MRD+ study at Memorial Sloan Kettering (HB-200 intervention for HPV16+ HNSCC with molecular relapse); multiple validation cohorts.",
    "clinicalTrialsCitations": "https://www.naveris.com/ | Naveris press release April 2024; https://pubmed.ncbi.nlm.nih.gov/32017652/ | Chera BS et al. J Clin Oncol 2020;38:1050-1058; https://pubmed.ncbi.nlm.nih.gov/35914212/ | Berger BM et al. Clin Cancer Res 2022;28:4292-4301",
    "clinicalSettings": ["Neoadjuvant", "Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Used across entire care continuum for HPV+ cancers: pre-treatment baseline, treatment response during neoadjuvant/adjuvant therapy, post-treatment MRD assessment, and long-term surveillance. Median 4-month lead time vs imaging.",
    "totalParticipants": 1076,
    "totalParticipantsNotes": "Multi-center surveillance cohort of 1,076 patients with PPV 95% (76/80) and NPV 95% (1,198/1,256) per Naveris clinical performance data. Additional validation across multiple published cohorts.",
    "numPublications": 35,
    "numPublicationsPlus": true,
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "First MRD test with Medicare coverage for HPV-driven cancers. Clinical LDT with ADLT designation. Unique tumor-naïve approach detecting viral-derived ctDNA rather than somatic mutations. Proven clinical utility in 35+ peer-reviewed publications."
  },
  {
    "id": "mrd-15",
    "sampleCategory": "Blood/Plasma",
    "sampleCollectionNotes": "Standard blood draw volume; specific volume not publicly disclosed.",
    "name": "Foresight CLARITY Lymphoma",
    "vendor": "Natera",
    "vendorOriginal": "Foresight Diagnostics",
    "approach": "Tumor-informed",
    "method": "PhasED-Seq (Phased variant Enrichment and Detection Sequencing): 150kb fixed capture panel leveraging somatic hypermutation in B-cell malignancies. Off-the-shelf panel (no custom reagent design) interrogates phased variants in stereotypical genomic regions. Requires concordant detection of ≥2 phased non-reference variants on same DNA molecule. Background error rate ~1.95E-08.",
    "cancerTypes": [
      "Diffuse large B-cell lymphoma (DLBCL)",
      "Large B-cell lymphoma (LBCL)",
      "Follicular lymphoma",
      "Classic Hodgkin lymphoma",
      "Multiple myeloma"
    ],
    "indicationsNotes": "Sensitive MRD assay for B-cell malignancies leveraging phased variant technology in somatic hypermutation regions. First ctDNA-MRD test included in NCCN Guidelines for B-Cell Lymphomas (Dec 2024). Acquired by Natera December 2025. Solid tumor version (up to 5,000 variants, 0.3 ppm LOD) in development but not yet clinically available.",
    "sensitivity": 90.62,
    "sensitivityCitations": "https://www.oncotarget.com/article/28654/text/ | Boehm N et al. Oncotarget 2025;16:329-336",
    "sensitivityNotes": "Positive percent agreement 90.62% (95% CI 74.98-98.02%) in DLBCL analytical validation. End-of-treatment MRD detection identified 90% of patients who later relapsed vs 45% for PET/CT.",
    "specificity": 97.65,
    "specificityCitations": "https://www.oncotarget.com/article/28654/text/ | Boehm N et al. Oncotarget 2025;16:329-336",
    "specificityNotes": "Negative percent agreement 97.65% (95% CI 87.43-99.94%) in DLBCL validation. False positive rate 0.24%.",
    "lod": "0.7 ppm",
    "lod95": "0.7 ppm",
    "lod95Citations": "https://www.natera.com/company/news/natera-acquires-foresight-diagnostics/",
    "lodCitations": "Boehm N et al. Oncotarget 2025;16:329-336; https://www.natera.com/company/news/natera-acquires-foresight-diagnostics/",
    "lodNotes": "LOD95 = 0.7 ppm per vendor and analytical validation paper. Solid tumor version (in development) achieves 0.3 ppm.",
    "leadTimeVsImaging": 200,
    "leadTimeVsImagingCitations": "https://www.natera.com/oncology/signatera-mrd-test/clarity/ | Foresight CLARITY product page",
    "leadTimeVsImagingNotes": "Detects relapse approximately 200 days earlier than PET/CT imaging in DLBCL. PhasED-Seq correctly identified 90% of patients who later relapsed vs 45% identified by PET/CT.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires tumor-derived material but flexible source: pre-treatment PLASMA (when tumor is shedding) OR tumor tissue. No tissue biopsy required if adequate pre-treatment plasma available.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "Requires matched normal sample per vendor confirmation.",
    "variantsTracked": "100s",
    "variantsTrackedNotes": "Fixed 150kb panel interrogates hundreds of phased variants in somatic hypermutation regions. No custom reagent design required (unlike solid tumor WGS approaches).",
    "initialTat": 8,
    "initialTatNotes": "8-10 days for new patient baseline. Off-the-shelf panel eliminates custom reagent design delay.",
    "followUpTat": 8,
    "followUpTatNotes": "8-10 days for MRD monitoring timepoints. Same turnaround as baseline due to fixed panel approach.",
    "bloodVolume": null,
    "bloodVolumeNotes": "Standard blood draw volume; specific volume not publicly disclosed.",
    "fdaStatus": "CLIA LDT – NOT FDA cleared/approved",
    "fdaStatusCitations": "Foresight website; CAP: 9346637, CLIA: 06D2287941",
    "reimbursement": "Not established",
    "reimbursementNote": "Research/trial use primarily. NCCN guideline inclusion may support future reimbursement pathway. Clinical launch expected 2026 post-Natera integration.",
    "cptCodes": null,
    "clinicalAvailability": "Research/trial use; limited clinical ordering. Central CLIA lab (Boulder, CO). Clinical launch expected 2026.",
    "clinicalTrials": "NCT06500273 (ALPHA3 - MRD+ LBCL patients post-remission); NCT06693830 (SHORTEN-ctDNA - ctDNA-guided chemotherapy de-escalation); multiple biopharma and academic partnerships",
    "clinicalTrialsCitations": "Foresight Diagnostics press releases 2025; ClinicalTrials.gov",
    "totalParticipants": 300,
    "totalParticipantsPlus": true,
    "totalParticipantsNotes": "300+ participants across multiple studies. JCO pooled analysis included 137 DLBCL patients from 5 prospective studies; additional patients in ongoing trials.",
    "numPublications": 40,
    "numPublicationsPlus": true,
    "numPublicationsCitations": "Foresight website; Natera acquisition announcement noted 15 abstracts at ASH 2025.",
    "clinicalSettings": ["Neoadjuvant", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated for MRD assessment during/after frontline therapy in DLBCL and surveillance monitoring. First ctDNA-MRD test in NCCN Guidelines for DLBCL. Used to adjudicate PET-positive results at end of therapy.",
    "isRUO": false,
    "isInvestigational": true,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CLIA-registered laboratory (CAP: 9346637, CLIA: 06D2287941). First ctDNA-MRD test in NCCN B-Cell Lymphoma guidelines. Acquired by Natera Dec 5, 2025 for $275M upfront + $175M earnouts.",
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN B-Cell Lymphomas V.2.2025 (Dec 2024)",
    "nccnGuidelinesNotes": "First ctDNA-MRD test named in NCCN Guidelines. Recommended to adjudicate PET-positive results at end of frontline DLBCL therapy (assay LOD <1ppm required).",
    "vendorDataSource": "John Truesdell (Natera/Foresight) Dec 2025; https://pubmed.ncbi.nlm.nih.gov/40353795/",
    "solidTumorVersionNotes": "Foresight CLARITY for solid tumors is in development (not clinically available). Uses WGS baseline with up to 5,000 phased+low-error variants and achieves 0.3 ppm LOD. Requires custom reagent design like other MRD products.",
    "acquisitionDetails": {
      "acquirer": "Natera",
      "date": "2025-12-05",
      "upfrontValueUSD": 275000000,
      "earnoutPotentialUSD": 175000000
    }
  },
  {
    "id": "mrd-16",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Standard collection: two 10mL Streck cfDNA tubes (20mL total).",
    "sampleCitations": "https://oncology.labcorp.com/",
    "name": "Invitae PCM",
    "vendor": "Labcorp (Invitae)",
    "approach": "Tumor-informed",
    "method": "Tumor-informed, whole-exome sequencing-based MRD assay: WES of tumor and matched normal identifies 18-50 patient-specific variants, which are tracked at high depth in plasma using Anchored Multiplex PCR (AMP) chemistry with error correction.",
    "cancerTypes": [
      "NSCLC",
      "Breast",
      "Colorectal",
      "Pancreatic",
      "Head and neck",
      "Multi-solid"
    ],
    "indicationsNotes": "Invitae Personalized Cancer Monitoring (PCM) pan-cancer tumor-informed MRD assay, now part of Labcorp following Aug 2024 acquisition. Co-developed with TRACERx consortium. FDA Breakthrough Device designation. Not indicated for hematological malignancies, CNS malignancies, or sarcomas.",
    "sensitivity": 76.9,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/39848827/ | Garcia-Murillas I et al. Ann Oncol 2025; TRACERx lung cancer studies",
    "sensitivityNotes": "76.9% clinical sensitivity in breast cancer monitoring phase for patients who relapsed. TRACERx NSCLC showed 93% (13/14) prediction of relapse post-resection.",
    "specificity": 100,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/39848827/ | Garcia-Murillas I et al. Ann Oncol 2025",
    "specificityNotes": "100% specificity in breast cancer monitoring cohort (n=61). ⚠️ Small clinical cohort; no false positives reported.",
    "smallSampleWarning": true,
    "validationCohortSize": 61,
    "validationCohortStudy": "Garcia-Murillas I et al. Ann Oncol 2025 (n=61 breast cancer)",
    "lod": "80 ppm",
    "lod95": null,
    "lodCitations": "https://www.labcorp.com/tests/480840/invitae-personalized-cancer-monitoring | Labcorp Invitae PCM specifications",
    "lodNotes": "LOD of 0.008% VAF (80 ppm) with 60ng cfDNA input and 18-50 variants at baseline threshold. LOD of 0.05% VAF (500 ppm) with 10ng cfDNA and 18 variants at monitoring threshold.",
    "leadTimeVsImaging": 351,
    "leadTimeVsImagingCitations": "https://pubmed.ncbi.nlm.nih.gov/39848827/ | Garcia-Murillas I et al. Ann Oncol 2025",
    "leadTimeVsImagingNotes": "Median lead time 11.7 months (351 days) before clinical relapse in breast cancer. TRACERx NSCLC showed median 70 days, up to 136 days in follow-up cohort.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires FFPE tumor tissue plus matched-normal blood for baseline WES panel design.",
    "requiresMatchedNormal": "Yes",
    "variantsTracked": "18-50",
    "variantsTrackedNotes": "Invitae algorithm selects 18-50 tumor-specific variants from WES results. Range allows balance of sensitivity in low vs high mutational burden cancers.",
    "initialTat": 21,
    "initialTatNotes": "Approximately 3 weeks for baseline panel design from tumor/normal WES.",
    "followUpTat": 10,
    "followUpTatNotes": "Monitoring timepoints typically reported within 10 days.",
    "bloodVolume": 20,
    "bloodVolumeNotes": "Standard collection: two 10mL Streck cfDNA tubes (20mL total).",
    "fdaStatus": "CLIA LDT; FDA Breakthrough Device designation",
    "fdaStatusCitations": "Invitae/Labcorp website; FDA BDD program.",
    "reimbursement": "Coverage emerging",
    "reimbursementNote": "Under Novitas MAC jurisdiction (not MolDX/Palmetto). Labcorp pursuing coverage pathways post-acquisition.",
    "cptCodes": null,
    "clinicalAvailability": "Clinical LDT – shipping (Metro Park, NJ laboratory)",
    "clinicalTrials": "TRACERx (NSCLC, ~850 pts); MARIA (pan-tumor); ARTEMIS (pancreatic); multiple breast and GI studies",
    "clinicalTrialsCitations": "Invitae/Labcorp press releases; ClinicalTrials.gov",
    "totalParticipants": 1000,
    "totalParticipantsNotes": "TRACERx alone enrolled ~850 pts; additional studies in breast, pancreatic, colorectal.",
    "numPublications": 15,
    "numPublicationsPlus": true,
    "numPublicationsCitations": "TRACERx consortium publications; Garcia-Murillas et al.",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "TRACERx consortium validated post-surgical MRD assessment (93% recurrence prediction in NSCLC) and longitudinal surveillance (median 11.7 month lead time in breast cancer).",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CAP-accredited, CLIA-certified laboratory (Metro Park, NJ). Acquired by Labcorp Aug 2024 via Invitae bankruptcy sale ($239M)."
  },
  {
    "id": "mrd-18",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "Approximately 20mL whole blood; plasma and buffy coat analyzed separately.",
    "sampleCitations": "https://www.carislifesciences.com/products-and-services/assure/",
    "name": "Caris Assure",
    "vendor": "Caris Life Sciences",
    "approach": "Tumor-naïve MRD (WES/WTS cfDNA + cfRNA)",
    "method": "AI-enabled whole exome and whole transcriptome sequencing (WES/WTS) from plasma cfDNA/cfRNA and buffy coat WBC DNA/RNA with machine learning MRD model; CHIP subtraction for accuracy",
    "methodCitations": "https://www.nature.com/articles/s41598-025-08986-0 | https://www.carislifesciences.com/physicians/physician-tests/caris-assure/",
    "cancerTypes": ["All solid tumors"],
    "targetPopulation": "Cancer patients requiring MRD detection and disease monitoring; tumor-naïve approach does not require prior tissue profiling",
    "indicationsNotes": "Multi-functional platform validated for MRD detection across solid tumors. Disease-free survival stratification: HR=33.4 (p<0.005) for MRD-positive vs MRD-negative patients. Also supports therapy selection and treatment response monitoring on same platform.",
    "sensitivity": 93.8,
    "sensitivityNotes": "93.8% sensitivity in MRD model validation. Trained on 3,439 patients and validated on independent set of 86 MRD patients. Tumor-naïve approach using AI-derived features from plasma.",
    "sensitivityCitations": "https://www.nature.com/articles/s41598-025-08986-0",
    "specificity": 99.6,
    "specificityNotes": "99.6% specificity (>99.9% in some cohorts) in MRD/monitoring validation.",
    "specificityCitations": "https://www.nature.com/articles/s41598-025-08986-0",
    "lod": "0.05% VAF",
    "lodCitations": "https://www.nature.com/articles/s41598-025-08986-0",
    "lodNotes": "Detection threshold approximately 0.05% VAF via WES/WTS cfDNA analysis.",
    "performanceNotes": "For MRD detection, disease-free survival of patients predicted to have an event (MRD-positive) was significantly shorter than those predicted MRD-negative (HR=33.4, p<0.005). For monitoring, HR=4.39, p=0.008. Uses tumor-naïve approach - no prior tissue profiling required.",
    "performanceCitations": "https://www.nature.com/articles/s41598-025-08986-0",
    "fdaStatus": "CLIA LDT",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage expanding; contact Caris for current payer coverage.",
    "clinicalAvailability": "Commercially available in US since late 2022",
    "availableRegions": ["US"],
    "initialTat": 14,
    "initialTatNotes": "Initial MRD assessment typically 10-14 business days.",
    "followUpTat": 14,
    "sampleType": "Whole blood",
    "bloodVolume": 20,
    "bloodVolumeNotes": "Approximately 20mL whole blood; plasma and buffy coat analyzed separately.",
    "clinicalTrials": "MRD model validated on 86 patients; monitoring validated on 101 patients; 3,439 training samples",
    "totalParticipants": 3626,
    "numPublications": 5,
    "numPublicationsPlus": true,
    "numPublicationsCitations": "https://www.nature.com/articles/s41598-025-08986-0",
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Validated for post-surgical MRD assessment (HR=33.4 for MRD+ vs MRD-) and longitudinal disease monitoring (HR=4.39). Tumor-naïve approach enables testing without prior tissue profiling.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "technologyDifferentiator": "Tumor-naïve MRD approach using AI/ML on WES/WTS data - no prior tissue profiling required. Only liquid biopsy sequencing both plasma and buffy coat for CHIP subtraction, improving accuracy over plasma-only assays."
  },
  {
    "id": "mrd-19",
    "sampleCategory": "Bone Marrow/Blood",
    "sampleTubeType": "EDTA",
    "sampleCollectionNotes": "Bone marrow: 1 mL aspirate recommended. Blood (CLL): 2 mL whole blood. Sample requirements vary by specimen type.",
    "sampleCitations": "https://www.adaptivebiotech.com/clonoseq/",
    "name": "clonoSEQ",
    "vendor": "Adaptive Biotechnologies",
    "approach": "Tumor-informed (Immunosequencing)",
    "method": "NGS-based immunosequencing of B-cell (IGH, IGK, IGL) and T-cell receptor gene rearrangements. Identifies patient-specific clonal DNA sequences ('barcodes') at diagnosis, then tracks these sequences in subsequent samples to quantify MRD with sensitivity to 10⁻⁶ (1 cancer cell per million).",
    "methodCitations": "https://www.clonoseq.com/about-clonoseq/ | https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-next-generation-sequencing-based-test-detect-very-low-levels-remaining-cancer",
    "cancerTypes": [
      "Multiple myeloma",
      "B-cell ALL",
      "CLL",
      "DLBCL",
      "Mantle cell lymphoma",
      "Other lymphoid malignancies"
    ],
    "cancerTypesNotes": "FDA-cleared for MM (bone marrow), B-ALL (bone marrow), and CLL (blood or bone marrow). Available as CLIA-validated LDT for DLBCL, MCL, and other lymphoid cancers.",
    "cancerTypesCitations": "https://www.clonoseq.com/technical-summary/",
    "targetPopulation": "Patients with lymphoid malignancies (like Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia; Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma) requiring MRD assessment during and after treatment to evaluate prognosis, monitor remission, and detect potential relapse.",
    "indicationsNotes": "First and only FDA-cleared MRD test for hematologic malignancies. Uses NGS immunosequencing to detect residual cancer cells at 100x greater sensitivity than standard flow cytometry. Two-step testing: Clonality (ID) test identifies trackable sequences at diagnosis; Tracking (MRD) tests monitor those sequences in subsequent samples.",
    "sensitivity": 95,
    "sensitivityPlus": true,
    "sensitivityNotes": "~95%+ clinical sensitivity. Detects MRD at 10⁻⁶ sensitivity (1 cancer cell per 1 million healthy cells) given sufficient sample input (20 μg DNA). This is 100x more sensitive than standard flow cytometry (10⁻⁴). Sensitivity is sample-dependent based on DNA input quantity.",
    "sensitivityCitations": "https://www.clonoseq.com/about-clonoseq/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/",
    "specificity": 99,
    "specificityPlus": true,
    "specificityNotes": "~99%+ analytical specificity. Validation demonstrated high specificity with well-characterized limit of blank (LoB) to minimize false positives from non-malignant clones.",
    "specificityCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/",
    "lod": "10⁻⁶ (1 in 1 million cells)",
    "lodNotes": "LoD of 1.9 malignant cells at 20 μg DNA input. Sensitivity scales with DNA input - higher DNA input enables deeper detection. Maximum sensitivity of 10⁻⁶ achievable with sufficient sample material.",
    "lodCitations": "https://www.clonoseq.com/wp-content/uploads/2021/08/PNL-10027-03_clonoSEQ-Technical-Information.pdf",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Does not require solid tumor tissue. Requires high-disease-burden baseline sample (fresh or archived) for initial Clonality (ID) test to identify trackable sequences: Fresh or archived sample from bone marrow aspirate, peripheral blood, or soft tissue. Subsequent clonoSEQ Tracking (MRD) uses standard fresh bone marrow or blood samples.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Does not require separate matched normal sequencing. Clonality criteria (≥3% of like sequences, ≥0.2% of total cells, etc.) distinguish malignant from normal B/T-cell populations.",
    "initialTat": 14,
    "initialTatNotes": "Initial Clonality (ID) test to identify trackable sequences: ~14 days from sample receipt.",
    "initialTatCitations": "https://www.clonoseq.com/ordering-clonoseq/ | https://www.childrensmn.org/references/lab/pathology/clonoseq.pdf",
    "followUpTat": 7,
    "followUpTatNotes": "Serial MRD monitoring (Tracking tests): ~7 days from sample receipt. Requires prior valid Clonality result.",
    "followUpTatCitations": "https://www.clonoseq.com/ordering-clonoseq/ | https://www.childrensmn.org/references/lab/pathology/clonoseq.pdf",
    "bloodVolume": null,
    "bloodVolumeNotes": "Bone marrow: 1 mL aspirate recommended. Blood (CLL): 2 mL whole blood. Sample requirements vary by specimen type.",
    "sampleRequirements": "Bone marrow aspirate (1 mL EDTA), peripheral blood (2 mL EDTA for CLL), or archived FFPE/slides. Fresh specimens preferred; stored specimens accepted with longer TAT.",
    "sampleRequirementsCitations": "https://www.clonoseq.com/ordering-clonoseq/",
    "fdaStatus": "FDA De Novo cleared (Sept 2018 for MM and B-ALL; Aug 2020 expanded for CLL in blood and bone marrow). CE-IVDR Class C certified (Aug 2024) - first IVDR-certified MRD test for lymphoid malignancies in EU. First FDA-cleared NGS-based MRD test.",
    "fdaApprovalDate": "2018-09-28",
    "fdaStatusCitations": "https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-next-generation-sequencing-based-test-detect-very-low-levels-remaining-cancer | https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-receives-expanded-fda-clearance",
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Multiple Myeloma, ALL, CLL Guidelines",
    "nccnGuidelinesNotes": "NCCN Category 2A recommendation. NGS-based MRD assessment specifically named for MM (at each treatment stage), ALL, and CLL.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1",
    "reimbursement": "Medicare",
    "reimbursementNote": "National Medicare coverage for MM, B-ALL, CLL, DLBCL, and MCL via MolDX program. Medicare CLFS rate: $2,007 per test (PLA 0364U); episode pricing $8,029 across all covered indications. Positive coverage from major commercial insurers for MM and ALL. 90% of patients pay $0 for testing.",
    "reimbursementCitations": "https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-announces-clinical-lab-fee-schedule",
    "cptCodes": "0364U",
    "codeType": "PLA",
    "medicareRate": 2007,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "listPrice": 2007,
    "listPriceNotes": "Medicare CLFS rate $2,007 per test as of January 2025. Episode pricing (full testing series) $8,029.",
    "listPriceCitations": "https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-announces-clinical-lab-fee-schedule",
    "clinicalAvailability": "Commercially available in US since 2018. Single-site assay performed at Adaptive Biotechnologies laboratory in Seattle, WA.",
    "clinicalAvailabilityCitations": "https://www.clonoseq.com/ordering-clonoseq/",
    "availableRegions": ["US", "EU", "International"],
    "availableRegionsNotes": "US: FDA-cleared IVD via Seattle lab. EU: CE-marked, available via Roche and regional partners. International availability via MedGenome (India) and other distributors.",
    "clinicalTrials": "Validated in major phase III trials including ALCYONE (706 pts, transplant-ineligible NDMM), POLLUX (569 pts, R/R MM), MASTER (daratumumab-KRd MRD-guided discontinuation), DETERMINATION (RVd ± ASCT), multiple ALL and CLL studies. Used in 25 of 28 NCCN cancer centers.",
    "clinicalTrialsCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/ | https://www.clonoseq.com/multiple-myeloma/",
    "totalParticipants": 5000,
    "totalParticipantsNotes": "Estimated >5,000 patients across published clinical validation studies. ALCYONE alone included 706 patients.",
    "totalParticipantsCitations": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/ | https://www.clonoseq.com/multiple-myeloma/",
    "numPublications": 100,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Extensive peer-reviewed evidence including validation studies in MM, ALL, CLL, lymphomas. Clinical data incorporated into FDA drug approvals and NCCN guidelines.",
    "clinicalSettings": ["Neoadjuvant", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated across treatment phases for hematologic malignancies: during induction/consolidation therapy, after treatment completion, and long-term surveillance. NCCN recommends MRD assessment at each treatment stage in MM.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": false,
    "regulatoryStatusNotes": "FDA-cleared IVD for MM, B-ALL, CLL. Additionally available as CLIA-validated LDT for DLBCL, MCL, and other lymphoid malignancies. Only FDA-cleared MRD test for hematologic malignancies.",
    "technologyDifferentiator": "Hematologic MRD test using immunosequencing of B/T-cell receptor genes - fundamentally different from solid tumor ctDNA assays. First and only FDA-cleared MRD test. 10⁻⁶ sensitivity (100x more sensitive than flow cytometry). Quantitative results track disease burden over time, not just positive/negative. Blood-based testing available for CLL reduces need for bone marrow biopsies."
  },
  {
    "id": "mrd-20",
    "sampleCategory": "Blood/Plasma",
    "sampleCollectionNotes": "Same sample requirements as standard Signatera (two Streck tubes).",
    "name": "Signatera Genome",
    "vendor": "Natera",
    "approach": "Tumor-informed (WGS)",
    "method": "Whole-genome sequencing-informed tumor-informed ctDNA assay using mPCR-NGS. WGS identifies patient-specific variants, then 64 clonal variants are selected and tracked via multiplex PCR with ultra-deep sequencing (up to 350,000x coverage per variant). Same proven mPCR workflow as standard Signatera but with enhanced sensitivity.",
    "methodCitations": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",
    "cancerTypes": [
      "Breast cancer",
      "NSCLC",
      "Melanoma",
      "Renal cell carcinoma",
      "Colorectal cancer",
      "Multi-solid tumors"
    ],
    "targetPopulation": "Patients with solid tumors requiring ultrasensitive MRD detection, particularly those where standard Signatera sensitivity may be insufficient or where maximal lead time to recurrence is desired",
    "indicationsNotes": "Genome-scale version of Signatera offering enhanced sensitivity (1 ppm LOD) and increased lead time to recurrence. Uses WGS instead of WES for variant identification, enabling selection of optimal 64 clonal variants for tracking. Same Medicare coverage as standard Signatera for covered indications.",
    "sensitivity": 94,
    "sensitivityNotes": "94% longitudinal sensitivity for detecting distant, extracranial recurrence in pan-cancer validation cohort (392 patients, >2,600 plasma samples across breast, NSCLC, melanoma, RCC, and CRC).",
    "sensitivityCitations": "https://www.natera.com/oncology/signatera-mrd-test/genome/ | George M, et al. ASCO 2025 poster",
    "specificity": 100,
    "specificityNotes": "100% specificity for distant, extracranial recurrence detection in pan-cancer validation cohort (n=392 patients, >2,600 samples).",
    "specificityCitations": "https://www.natera.com/oncology/signatera-mrd-test/genome/ | George M, et al. ASCO 2025 poster",
    "validationCohortSize": 392,
    "validationCohortStudy": "Pan-cancer cohort ASCO 2025 (392 patients, >2,600 samples across 5 tumor types)",
    "lod": "1 ppm",
    "lod95": "1 ppm",
    "lod95Citations": "https://www.natera.com/oncology/signatera-genome/",
    "lodNotes": "Ultra-sensitive detection down to 1 part per million (1 ppm), representing ~100x improvement over standard WES-based Signatera. Achieved through tracking 64 variants (vs 16) with ultra-deep sequencing.",
    "lodCitations": "https://www.natera.com/oncology/signatera-genome/",
    "leadTimeVsImaging": null,
    "leadTimeVsImagingNotes": "Increased lead times to recurrence compared to standard Signatera due to enhanced sensitivity. ctDNA-positive patients had 36x higher risk of relapse than ctDNA-negative patients.",
    "leadTimeVsImagingCitations": "https://www.natera.com/oncology/signatera-mrd-test/genome/ | George M, et al. ASCO 2025 poster",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires tumor tissue for whole-genome sequencing to identify patient-specific variants. Same sample requirements as standard Signatera.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "Matched normal (blood) required for germline filtering.",
    "variantsTracked": "64",
    "variantsTrackedNotes": "64 highly curated clonal variants selected for optimized balance of ultra-sensitivity and high specificity (vs 16 variants in standard Signatera).",
    "variantsTrackedCitations": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",
    "initialTat": 28,
    "initialTatNotes": "Initial result in approximately 4 weeks (vs ~2 weeks for standard Signatera) due to WGS requirement.",
    "followUpTat": 7,
    "followUpTatNotes": "Subsequent monitoring results in 7-10 days, same as standard Signatera.",
    "bloodVolume": null,
    "bloodVolumeNotes": "Same sample requirements as standard Signatera (two Streck tubes).",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Laboratory-developed test. Uses same Medicare coverage pathway as FDA-cleared Signatera for covered indications.",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",
    "vendorNCCNAlignmentNotes": "Vendor claims same NCCN alignment as standard Signatera. NCCN recommends ctDNA testing concepts but does not specifically name Signatera Genome by brand.",
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Colon Cancer, Rectal Cancer V.2.2025 (same as Signatera)",
    "nccnGuidelinesNotes": "Shares Signatera citations and validation data referenced in NCCN guidelines. Same ctDNA platform with expanded variant tracking.",
    "reimbursement": "Medicare",
    "reimbursementNote": "Same Medicare coverage as standard Signatera for covered indications: Stage II-IV CRC, Stage IIb+ breast cancer, MIBC, Stage I-III NSCLC surveillance, Stage II-IV ovarian cancer, and ICI response monitoring for any solid tumor.",
    "reimbursementCitations": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",
    "cptCodes": "0239U",
    "codeType": "PLA",
    "medicareRate": 3500,
    "medicareStatus": "Priced",
    "adltStatus": true,
    "listPrice": 3500,
    "listPriceNotes": "Expected same pricing as standard Signatera ($3,500 Medicare CLFS rate).",
    "clinicalAvailability": "Commercially available via Natera. Can only be ordered for new patients (cannot convert existing Signatera orders).",
    "clinicalAvailabilityCitations": "https://www.natera.com/oncology/signatera-advanced-cancer-detection/signatera-for-genome/",
    "clinicalTrials": "Pan-cancer validation in 392 patients with breast, NSCLC, melanoma, RCC, and CRC across >2,600 plasma samples (ASCO 2025).",
    "clinicalTrialsCitations": "https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3142",
    "totalParticipants": 392,
    "totalParticipantsNotes": "392 patients in initial pan-cancer validation cohort with >2,600 plasma samples analyzed.",
    "numPublications": 1,
    "numPublicationsNotes": "Initial clinical data presented at ASCO 2025. Backed by >100 publications for standard Signatera platform.",
    "clinicalSettings": ["Neoadjuvant", "Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Same clinical settings as standard Signatera with enhanced 1 ppm sensitivity. Validates across neoadjuvant, post-surgical, post-adjuvant, and surveillance settings in breast, NSCLC, melanoma, RCC, CRC.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CLIA-certified LDT leveraging Natera's established Signatera infrastructure. Uses proven mPCR-NGS workflow with WGS-informed variant selection for enhanced sensitivity.",
    "technologyDifferentiator": "WGS-informed evolution of Signatera tracking 64 variants (vs 16) at 1 ppm LOD (vs ~100 ppm). Ultra-deep sequencing up to 350,000x coverage per variant. Designed for cases requiring maximum sensitivity and lead time. Same trusted mPCR workflow backed by >1M Signatera tests."
  },
  {
    "id": "mrd-21",
    "sampleCategory": "Blood/Plasma",
    "sampleCollectionNotes": "Standard blood collection; specific volume not publicly disclosed.",
    "name": "Latitude",
    "vendor": "Natera",
    "approach": "Tumor-naïve (methylation)",
    "method": "Tissue-free, blood-based MRD test using targeted methylation panel composed of differentially methylated regions (DMRs) specifically designed for colorectal cancer. Does not require tumor tissue - analyzes cfDNA methylation patterns directly from blood.",
    "methodCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "cancerTypes": [
      "Colorectal cancer"
    ],
    "targetPopulation": "CRC patients requiring MRD detection when tumor tissue is unavailable, insufficient, or when faster turnaround is needed",
    "indicationsNotes": "Tissue-free MRD test for colorectal cancer. Ideal for patients where tumor tissue is not available for Signatera. Uses methylation-based approach rather than somatic variant tracking. Currently CRC-only; expansion to other cancers expected.",
    "sensitivity": 81,
    "sensitivityNotes": "81% longitudinal sensitivity (84% for colon cancer specifically). 58% single time point sensitivity. Validated in CIRCULATE-JAPAN GALAXY Study.",
    "sensitivityCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/ | CIRCULATE-JAPAN GALAXY Study",
    "specificity": 97,
    "specificityNotes": "97% sample-level specificity in validation cohort.",
    "specificityCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "lod": "0.01% VAF",
    "lodCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "lodNotes": "Detection threshold approximately 0.01% VAF via methylation-based approach.",
    "leadTimeVsImaging": 4.6,
    "leadTimeVsImagingNotes": "4.6 months median lead time before radiographic relapse in validation study.",
    "leadTimeVsImagingCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Tissue-free assay - does not require tumor tissue. Key differentiator from Signatera.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Methylation-based approach does not require matched normal for variant filtering.",
    "variantsTracked": null,
    "variantsTrackedNotes": "Uses methylation markers (DMRs) rather than somatic variants.",
    "initialTat": 7,
    "initialTatCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "initialTatNotes": "Fast turnaround time (~7 days) since no tumor sequencing required.",
    "followUpTat": 7,
    "followUpTatNotes": "Subsequent monitoring with same fast TAT as initial test.",
    "bloodVolume": null,
    "bloodVolumeNotes": "Standard blood collection; specific volume not publicly disclosed.",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Laboratory-developed test. Not FDA cleared.",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Reimbursement status for Latitude specifically not yet established. May be covered under existing MRD codes for CRC.",
    "clinicalAvailability": "Commercially available via Natera for colorectal cancer patients",
    "clinicalAvailabilityCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "clinicalTrials": "Validated in CIRCULATE-JAPAN GALAXY Study: 195 CRC patients, 1,300+ plasma samples. Latitude-positive patients had HR=10 for DFS (p<0.001). Latitude-positive patients who did not receive ACT had 100% relapse rate (26/26 PPV).",
    "clinicalTrialsCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "clinicalSettings": ["Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Tissue-free CRC MRD validated for post-surgical and post-adjuvant assessment, plus surveillance monitoring. GALAXY study showed HR=10 for recurrence in MRD+ patients.",
    "totalParticipants": 195,
    "totalParticipantsNotes": "195 patients in CIRCULATE-JAPAN GALAXY validation study with 1,300+ plasma samples.",
    "numPublications": 2,
    "numPublicationsNotes": "Validation data from CIRCULATE-JAPAN GALAXY Study. Part of Natera's extensive MRD publication portfolio.",
    "numPublicationsCitations": "https://www.natera.com/oncology/latitude-tissue-free-mrd/",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CLIA-certified LDT from Natera. Complements Signatera for cases where tumor tissue is unavailable.",
    "technologyDifferentiator": "Tissue-free MRD for CRC - no tumor tissue required. Uses methylation-based detection rather than somatic variant tracking. Enables MRD testing when tissue is unavailable, insufficient, or degraded. Part of Natera's comprehensive MRD portfolio alongside Signatera and Signatera Genome."
  },
  {
    "id": "mrd-22",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "20 mL whole blood required. 1-10 mL plasma used for cfDNA extraction.",
    "name": "CancerDetect",
    "vendor": "IMBdx",
    "approach": "Tumor-informed (hybrid)",
    "method": "Tumor-informed hybrid approach combining large-scale personalized mutation tracking (up to 300 patient-specific variants from tumor WES) with tumor-agnostic hotspot regions covering 58 clinically actionable mutations across 15 genes. Uses hybridization capture with UMI-based error suppression and ultra-deep sequencing (~100,000x). Proprietary HQS technology for false positive reduction.",
    "methodCitations": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0334282 | https://www.nature.com/articles/s41416-023-02300-3",
    "cancerTypes": [
      "Colorectal cancer",
      "Breast cancer",
      "Gastric cancer"
    ],
    "targetPopulation": "Stage II-III solid tumor patients requiring MRD detection post-surgery, particularly CRC, breast, and gastric cancer",
    "indicationsNotes": "Korean-developed tumor-informed MRD test using large-scale mutation profiling strategy. Tracks median 185 variants per patient (up to 300). Designated as 'Innovative Medical Technology' by Korean Ministry of Health and Welfare (similar to FDA Breakthrough Device). Used in nationwide phase III interventional trial (NCT05534087) for MRD-guided treatment escalation.",
    "sensitivity": 61.9,
    "sensitivityNotes": "Clinical sensitivity 61.9% for predicting recurrence within 3 years at postoperative 3-week timepoint. In silico simulation shows increased sensitivity with more monitoring variants.",
    "sensitivityCitations": "https://www.nature.com/articles/s41416-023-02300-3",
    "specificity": 99.9,
    "specificityNotes": "99.9% analytical specificity for bespoke (personalized) regions. 95% specificity for hotspot regions. ⚠️ Analytical validation; clinical cohort n=98.",
    "specificityCitations": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0334282",
    "smallSampleWarning": true,
    "validationCohortSize": 98,
    "validationCohortStudy": "British Journal of Cancer 2023 (n=98 CRC patients)",
    "lod": "0.0005% VAF",
    "lod95": "0.001%",
    "lod95Citations": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0302129",
    "lodNotes": "Detection threshold ~0.0005% VAF (5 ppm) for bespoke regions; LOD95 of 0.001% (10 ppm). Limit of blank 0.0003% for bespoke regions. Achieved through large-scale mutation tracking combined with ultra-deep sequencing.",
    "lodCitations": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0302129",
    "leadTimeVsImaging": null,
    "leadTimeVsImagingNotes": "Postoperative MRD positivity strongly associated with recurrence (adjusted HR 8.40, 95% CI 3.49-20.2). Patients with MRD clearance after adjuvant therapy showed significantly better outcomes.",
    "leadTimeVsImagingCitations": "https://www.nature.com/articles/s41416-023-02300-3",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires tumor tissue for whole-exome sequencing to identify patient-specific variants. Fresh frozen tissue preferred.",
    "requiresMatchedNormal": "Yes",
    "requiresMatchedNormalNotes": "PBMC sequencing used to filter germline variants and CHIP mutations from cfDNA results.",
    "variantsTracked": "Up to 300",
    "variantsTrackedNotes": "Median 185 variants tracked per patient (range 116-300). Large-scale mutation profiling strategy shown to improve sensitivity at low ctDNA fractions (<0.01%).",
    "variantsTrackedCitations": "https://www.nature.com/articles/s41416-023-02300-3",
    "initialTat": 28,
    "initialTatNotes": "Initial TAT 28 days (4 weeks). Reduced from previous 8-10 weeks in earlier version.",
    "followUpTat": 14,
    "followUpTatNotes": "Follow-up monitoring TAT 14 days (2 weeks).",
    "bloodVolume": "20 mL",
    "bloodVolumeNotes": "20 mL whole blood required. 1-10 mL plasma used for cfDNA extraction.",
    "bloodVolumeCitations": "https://www.imbdx.com/eng/about/detect.php",
    "cfdnaInput": "30 ng",
    "cfdnaInputCitations": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0334282",
    "fdaStatus": "Not FDA cleared",
    "fdaStatusNotes": "Korean 'Innovative Medical Technology' designation from Ministry of Health and Welfare (analogous to FDA Breakthrough Device Designation). Not FDA cleared for US market.",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://www.cancerdetect.com/",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Korean national health insurance coverage under Innovative Medical Technology pathway. Not available in US market.",
    "clinicalAvailability": "Commercially available in South Korea via IMBdx",
    "clinicalAvailabilityCitations": "https://www.imbdx.com/eng/",
    "availableRegions": ["South Korea"],
    "availableRegionsNotes": "Currently available in South Korea. International expansion potential.",
    "clinicalTrials": "Phase III interventional trial (NCT05534087) for MRD-guided treatment escalation in CRC. Validation studies in breast cancer (AACR 2025, SABCS 2023/2025) and gastric cancer (AACR 2025). Original CRC validation: 98 patients, Stage II-III, median 36.3 months follow-up.",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05534087 | https://www.nature.com/articles/s41416-023-02300-3",
    "totalParticipants": 98,
    "totalParticipantsNotes": "98 patients in primary CRC validation study. Phase III trial (NCT05534087) enrolling ~1,200 CRC patients.",
    "numPublications": 2,
    "numPublicationsNotes": "British Journal of Cancer 2023 (clinical validation), PLOS One 2025 (analytical validation). Multiple conference abstracts at AACR 2025, SABCS 2023/2025.",
    "numPublicationsCitations": "https://www.nature.com/articles/s41416-023-02300-3 | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0334282",
    "clinicalSettings": ["Post-Surgery", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated for postoperative MRD assessment at 3 weeks (61.9% sens for recurrence) and after adjuvant therapy. MRD clearance post-adjuvant associated with better outcomes. Phase III interventional trial (NCT05534087) for MRD-guided treatment.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "Commercially available in South Korea with Innovative Medical Technology designation. Previously known as AlphaLiquid®Detect.",
    "technologyDifferentiator": "Large-scale mutation tracking (up to 300 variants vs typical 16-50) combined with tumor-agnostic hotspot panel. Korean-developed with strong regulatory pathway. Ultra-sensitive detection (0.001% LOD) through expanded variant coverage rather than deeper sequencing alone. Hybrid approach enables detection of both original tumor mutations and de novo resistance mutations.",
    "vendorVerified": true,
    "vendorRequestedChanges": "2025-12-29: Vendor verified by Sunghoon Heo (sunghoon.heo@imbdx.com), IMBdx. Updated bloodVolume to 20 mL, added cfdnaInput 30 ng per vendor with citations."
  },
  {
    "id": "mrd-23",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "20 mL blood in cfDNA tubes required for testing.",
    "name": "LymphoVista",
    "vendor": "LIQOMICS",
    "approach": "Tumor-informed (ctDNA sequencing)",
    "method": "Targeted ctDNA sequencing using duplex barcodes and disease-specific gene panels optimized for lymphomas. Incorporates non-coding regions with highly frequent genetic alterations. Two variants: LymphoVista (B-cell lymphomas, 83 kbp panel) and LymphoVista HL (Hodgkin lymphoma, modified panel). Two-step workflow: initial genotyping identifies patient-specific mutations, followed by serial MRD monitoring.",
    "methodCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping | https://liqomics.com/en/lymphovista/",
    "cancerTypes": [
      "Diffuse large B-cell lymphoma (DLBCL)",
      "Follicular lymphoma",
      "Mantle cell lymphoma",
      "Marginal zone lymphoma",
      "Burkitt lymphoma",
      "CNS lymphomas",
      "Hodgkin lymphoma (via LymphoVista HL)"
    ],
    "cancerTypesNotes": "LymphoVista covers all B-cell lymphomas. LymphoVista HL uses a slightly modified gene panel specifically optimized for Hodgkin lymphoma genomics.",
    "cancerTypesCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping",
    "targetPopulation": "Patients with B-cell lymphomas or Hodgkin lymphoma requiring MRD assessment during treatment (e.g., after 2 cycles), post-treatment surveillance, or monitoring after CAR-T cell therapy or salvage chemotherapy.",
    "indicationsNotes": "Designed for both interim response assessment during active treatment AND post-treatment MRD monitoring. Validated in relapsed/refractory DLBCL patients post-CAR-T/chemo and in advanced-stage Hodgkin lymphoma (HD21 trial). Addresses lymphoma-specific MRD needs distinct from solid tumor ctDNA assays.",
    "sensitivity": 100,
    "sensitivityNotes": "At MRD level of 7.0×10⁻⁵: 100% sensitivity, 93% specificity, 94% accuracy (LymphoVista). ⚠️ Validation cohort n=160 (72 HL + 88 DLBCL). For variant detection (genotyping) at ≥0.5% mAF: 93.86% sensitivity / 99.999% specificity.",
    "sensitivityCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping | https://library.ehaweb.org/eha/2024/eha2024-congress/419348/",
    "smallSampleWarning": true,
    "validationCohortSize": 160,
    "validationCohortStudy": "HD21 trial (n=72 HL) + EHA 2024 DLBCL (n=88)",
    "specificity": 93,
    "specificityNotes": "93% specificity at MRD level of 7.0×10⁻⁵. For variant detection (genotyping): 99.999% specificity (LymphoVista) and 99.99% specificity (LymphoVista HL).",
    "specificityCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping | https://library.ehaweb.org/eha/2024/eha2024-congress/419348/",
    "ppv": 92.1,
    "ppvNotes": "92.1% PPV determined in relapsed/refractory DLBCL patients treated with various therapies including CAR-T cells and high-dose chemotherapy (Schleifenbaum et al. EHA 2024).",
    "ppvCitations": "https://library.ehaweb.org/eha/2024/eha2024-congress/419348/",
    "lod": "6.69 × 10⁻⁶",
    "lodNotes": "Limit of detection 6.69 × 10⁻⁶ (LymphoVista) and 6.54 × 10⁻⁶ (LymphoVista HL). 100% accuracy for MRD values >3.04 × 10⁻⁵ (LymphoVista) and >1.76 × 10⁻⁵ (LymphoVista HL). Duplex sequencing enables ultrasensitive detection.",
    "lodCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping",
    "leadTimeVsImaging": null,
    "leadTimeVsImagingNotes": "MRD positivity after 2 cycles of treatment (MRD-2) strongly predictive of outcomes. In HD21 trial, MRD-2-positive patients had 72.2% vs 95.3% 4-year PFS (HR 6.9, p<0.0001). MRD status prognostic even in PET-2-negative patients, suggesting molecular assessment adds value beyond imaging.",
    "leadTimeVsImagingCitations": "Mattlener et al. ASH 2024",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Blood-based assay. Initial genotyping can use blood sample (ctDNA) or tissue if available. Does not require solid tumor biopsy.",
    "requiresMatchedNormal": "No",
    "requiresMatchedNormalNotes": "Genotyping identifies lymphoma-specific mutations from ctDNA without requiring matched normal sequencing.",
    "initialTat": "10 days",
    "initialTatNotes": "Initial genotyping test to identify patient-specific mutations: 10 days.",
    "followUpTat": "10 days",
    "followUpTatNotes": "Serial MRD monitoring of known mutations: 10 days from sample receipt.",
    "bloodVolume": "20 mL",
    "bloodVolumeNotes": "20 mL blood in cfDNA tubes required for testing.",
    "sampleRequirements": "20 mL blood in cfDNA preservation tubes",
    "sampleRequirementsCitations": "https://liqomics.com/en/lymphovista/",
    "fdaStatus": "Not FDA-approved (EU/International LDT)",
    "fdaStatusNotes": "Laboratory-developed test offered from LIQOMICS laboratory in Cologne, Germany. CE marking status not specified. Primarily serves European market.",
    "vendorClaimsNCCNAlignment": true,
    "vendorNCCNAlignmentCitation": "https://lymphovista.com/",
    "vendorNCCNAlignmentNotes": "ctDNA testing for MRD in DLBCL recently added to NCCN Guidelines (December 2024) following Foresight CLARITY inclusion. LymphoVista not specifically named but methodology aligns with emerging guideline recommendations for ctDNA-based MRD in lymphoma.",
    "reimbursement": "Not established (EU)",
    "reimbursementNote": "Pricing: €2,965 for initial genotyping, €1,985 per MRD monitoring sample. Reimbursement varies by EU country and healthcare system. Not available in US market.",
    "reimbursementCitations": "https://liqomics.com/en/lymphovista/",
    "listPrice": 2965,
    "listPriceNotes": "€2,965 for initial genotyping test; €1,985 per subsequent MRD monitoring sample. Pricing in EUR.",
    "listPriceCitations": "https://liqomics.com/en/lymphovista/",
    "clinicalAvailability": "Commercially available in Europe via LIQOMICS laboratory (Cologne, Germany). Single-site assay.",
    "clinicalAvailabilityNotes": "Academic spin-off from University of Cologne, founded 2021. Strong ties to German Hodgkin Study Group (GHSG). Available for clinical use and research collaborations.",
    "clinicalAvailabilityCitations": "https://liqomics.com/en/about/",
    "availableRegions": ["EU", "Germany"],
    "availableRegionsNotes": "Primary market is Europe. Based in Cologne, Germany. International availability via direct ordering.",
    "clinicalTrials": "HD21 Phase III trial (Hodgkin lymphoma, BrECADD vs eBEACOPP, 72 patients in MRD validation subset); EHA 2024 DLBCL validation (88 patients, 326 samples, r/r setting including CAR-T); ISHL13 2024 presentations",
    "clinicalTrialsCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping | https://library.ehaweb.org/eha/2024/eha2024-congress/419348/",
    "totalParticipants": 160,
    "totalParticipantsNotes": "72 patients in HD21 Hodgkin lymphoma validation (ASH 2024); 88 patients in DLBCL validation (EHA 2024, 326 samples).",
    "numPublications": 2,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Key conference presentations: Mattlener et al. ASH 2024 (LymphoVista HL validation in Hodgkin lymphoma); Schleifenbaum et al. EHA 2024 (LymphoVista validation in DLBCL). Peer-reviewed manuscripts under review/in submission as of December 2025.",
    "numPublicationsCitations": "https://ashpublications.org/blood/article/144/Supplement%201/4355/533429/Lymphovista-HL-a-Validated-Assay-for-Genotyping",
    "clinicalSettings": ["Neoadjuvant", "Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Validated for interim response assessment (after 2 treatment cycles), post-treatment MRD assessment, and long-term surveillance. HD21 trial showed MRD-2 positivity prognostic even in PET-negative patients (HR 6.9 for PFS).",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "European LDT offered from CLIA-equivalent laboratory in Germany. Strong academic validation via GHSG HD21 trial data. Not FDA-approved; no current US market presence.",
    "technologyDifferentiator": "Lymphoma-specific ctDNA MRD test addressing an underserved niche - most competitors focus on solid tumors or use immunosequencing (clonoSEQ) for heme malignancies. Uses duplex sequencing with disease-optimized gene panels for lymphoma genomics. Founded by Sven Borchmann MD/PhD, a leading Hodgkin lymphoma researcher at University of Cologne/GHSG. Dual utility: both interim assessment during treatment and post-treatment MRD surveillance. Positioned as ctDNA alternative to PET for molecular response assessment in lymphoma.",
    "vendorVerified": true,
    "vendorRequestedChanges": "2025-12-28: Vendor verified by Jens Winter (jens.winter@liqomics.com), LIQOMICS. No edits requested - all data confirmed accurate."
  },
  {
    "id": "mrd-24",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": "20 mL blood in cfDNA preservation tubes required.",
    "name": "CancerVista",
    "vendor": "LIQOMICS",
    "approach": "Tumor-agnostic",
    "method": "Technically validated ctDNA assay for multi-solid tumor MRD detection. Optimized characteristic mutations across diverse solid tumors.",
    "cancerTypes": [
      "Bladder",
      "Brain",
      "Breast",
      "Cervix",
      "Colorectal",
      "Esophagus",
      "Head and neck",
      "Kidney",
      "Liver",
      "Lung",
      "Ovary",
      "Pancreas",
      "Prostate",
      "Skin",
      "Stomach",
      "Thyroid",
      "Uterus"
    ],
    "cancerTypesNotes": "Multi-solid tumor assay covering 17 anatomical sites including bladder, brain, breast, cervix, colorectal, esophagus, head and neck, kidney, liver, lung, ovary, pancreas, prostate, skin, stomach, thyroid, and uterus.",
    "indicationsNotes": "Technically validated assay for MRD detection across multiple solid tumor types. Gene spectrum optimized for characteristic mutations of diverse solid tumors.",
    "sensitivity": 80,
    "sensitivityNotes": "MRD Detection: 80% sensitivity at detection threshold of 2.5×10⁻⁵ for MRD levels >5.1×10⁻⁵. Variant Detection: 93.17% sensitivity for variants with minor allele frequency (mAF) ≥1%.",
    "sensitivityCitations": "https://liqomics.com/en/cancervista/ | Vendor data (Jens Winter, LIQOMICS, Dec 2025)",
    "specificity": 96.7,
    "specificityNotes": "MRD Detection: 96.7% specificity at detection threshold of 2.5×10⁻⁵. Variant Detection: >99% specificity for variants with mAF ≥1%.",
    "specificityCitations": "https://liqomics.com/en/cancervista/ | Vendor data (Jens Winter, LIQOMICS, Dec 2025)",
    "accuracy": 94.3,
    "accuracyNotes": "94.3% accuracy for MRD levels >5.1×10⁻⁵ at detection threshold of 2.5×10⁻⁵.",
    "lod": "3.30 × 10⁻⁶",
    "lodNotes": "Limit of detection 3.30×10⁻⁶. Detection threshold set at 2.5×10⁻⁵ for clinical reporting.",
    "lodCitations": "https://liqomics.com/en/cancervista/ | Vendor data (Jens Winter, LIQOMICS, Dec 2025)",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Tumor-agnostic blood-based assay; does not require prior tumor tissue.",
    "requiresMatchedNormal": "No",
    "initialTat": "10 days",
    "initialTatNotes": "10 days from sample receipt to result.",
    "followUpTat": "10 days",
    "followUpTatNotes": "10 days for follow-up monitoring samples.",
    "bloodVolume": "20 mL",
    "bloodVolumeNotes": "20 mL blood in cfDNA preservation tubes required.",
    "sampleRequirements": "20 mL blood in cfDNA tubes",
    "fdaStatus": "Not FDA-approved (EU/International LDT)",
    "fdaStatusNotes": "Technically validated assay offered from LIQOMICS laboratory in Cologne, Germany. Primarily serves European market.",
    "reimbursement": "Not established (EU)",
    "reimbursementNote": "Reimbursement varies by EU country and healthcare system. Not available in US market.",
    "clinicalAvailability": "Commercially available in Europe via LIQOMICS laboratory (Cologne, Germany).",
    "clinicalAvailabilityNotes": "Academic spin-off from University of Cologne, founded 2021. Available for clinical use.",
    "clinicalAvailabilityCitations": "https://liqomics.com/",
    "availableRegions": ["EU", "Germany"],
    "availableRegionsNotes": "Primary market is Europe. Based in Cologne, Germany.",
    "clinicalTrials": null,
    "clinicalSettings": ["Post-Surgery", "Surveillance"],
    "clinicalSettingsNotes": "Technically validated for MRD detection; clinical utility studies ongoing.",
    "numPublications": 1,
    "numPublicationsNotes": "Analytical validation complete; peer-reviewed publications pending. Conference presentations at LIQOMICS scientific meetings.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "Technically validated assay. European LDT offered from LIQOMICS laboratory in Germany.",
    "technologyDifferentiator": "Multi-solid tumor MRD assay from LIQOMICS (same vendor as lymphoma-focused LymphoVista). Ultra-sensitive detection with LoD of 3.30×10⁻⁶. Covers 17 anatomical sites with optimized mutation panels for diverse solid tumors.",
    "vendorVerified": true,
    "vendorRequestedChanges": "2025-12-15: Initial entry created based on specifications provided by Jens Winter (LIQOMICS). Includes analytical validation data for variant detection and MRD detection performance. 2025-12-28: Vendor verified by Jens Winter (jens.winter@liqomics.com), LIQOMICS. No edits requested - all data confirmed accurate."
  },
  {
    "id": "mrd-25",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 16,
    "sampleVolumeMin": 16,
    "sampleTubeType": "Cell-Free DNA BCT",
    "sampleTubeCount": 2,
    "sampleCollectionNotes": ">16ml blood volume required per vendor.",
    "sampleCitations": "https://www.brbiotech.com/",
    "name": "CanCatch Custom",
    "vendor": "Burning Rock Dx (brbiotech)",
    "approach": "Tumor-informed",
    "method": "Tumor-informed personalized MRD assay (also known as PROPHET - Patient-specific pROgnostic and Potential tHErapeutic marker Tracking). WES of tumor and matched normal identifies up to 50 patient-specific variants, which are tracked at 100,000x ultra-deep sequencing in plasma.",
    "methodCitations": "https://doi.org/10.1016/j.ccell.2023.08.010 | https://pubmed.ncbi.nlm.nih.gov/37683638/",
    "cancerTypes": [
      "NSCLC",
      "Colorectal",
      "Esophageal",
      "GIST"
    ],
    "cancerTypesNotes": "Clinical data published in NSCLC (Cancer Cell 2023), esophageal squamous cell carcinoma (Molecular Cancer 2025), colorectal cancer, and gastrointestinal stromal tumors (ASCO 2025).",
    "indicationsNotes": "Tumor-informed personalized MRD assay from Burning Rock Dx (NASDAQ: BNR). Tracks up to 50 patient-specific variants identified from tumor/normal WES. Commercial trade name is CanCatch Custom; also referred to as PROPHET in academic publications.",
    "sensitivity": 98.7,
    "sensitivityCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "sensitivityNotes": "98.7% sensitivity reported by vendor. In MEDAL NSCLC study (n=181), preoperative ctDNA detection rates were: Stage IA 15.7%, IB 40%, II 75%, III 82.6%. Landmark sensitivity (3-30 days post-surgery) was 45%.",
    "sensitivityStagesReported": "IA: 15.7%, IB: 40%, II: 75%, III: 82.6% (preoperative)",
    "stageIISensitivity": 75,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37683638/ | Chen et al. Cancer Cell 2023",
    "stageIISensitivityNotes": "75% preoperative detection rate in Stage II NSCLC patients (Chen et al., Cancer Cell 2023).",
    "stageIIISensitivity": 82.6,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37683638/ | Chen et al. Cancer Cell 2023",
    "stageIIISensitivityNotes": "82.6% preoperative detection rate in Stage III NSCLC patients (Chen et al., Cancer Cell 2023).",
    "landmarkSensitivity": 45,
    "landmarkSensitivityNotes": "45% sensitivity at landmark timepoint (3-30 days post-surgery) in NSCLC cohort.",
    "landmarkSensitivityCitations": "https://doi.org/10.1016/j.ccell.2023.08.010",
    "specificity": 99,
    "specificityPlus": true,
    "specificityCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "specificityNotes": ">99.0% specificity reported by vendor.",
    "validationCohortSize": 181,
    "validationCohortStudy": "MEDAL study (NCT03634826) - 181 patients, 760 plasma samples",
    "lod": "0.004%",
    "lod95": "0.004%",
    "lodCitations": "https://doi.org/10.1016/j.ccell.2023.08.010 | Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "lodNotes": "LoD as low as 0.004% (4 ppm) per vendor. Analytical validation using Seracare ctDNA MRD Panel Mix confirmed similar performance.",
    "leadTimeVsImaging": 299,
    "leadTimeVsImagingCitations": "https://doi.org/10.1016/j.ccell.2023.08.010",
    "leadTimeVsImagingNotes": "Median lead time of 299 days (~10 months) to radiologically confirmed recurrence in NSCLC cohort (Chen et al., Cancer Cell 2023).",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires tumor tissue for WES-based personalized panel design.",
    "requiresMatchedNormal": "Yes",
    "variantsTracked": "50",
    "variantsTrackedNotes": "Up to 50 highly ranked patient-specific markers selected from tumor/normal WES. Panel designed to cover selected markers with 100,000x ultra-deep sequencing.",
    "initialTat": 14,
    "initialTatNotes": "14 days TAT per vendor.",
    "followUpTat": 14,
    "followUpTatNotes": "14 days TAT for monitoring samples per vendor.",
    "tat": 14,
    "tatNotes": "14 days turnaround time per vendor submission.",
    "listPrice": "$4,000",
    "listPriceNotes": "List price $4,000 (may vary depending on test package) per vendor.",
    "fdaStatus": "Not FDA-approved (China/International LDT)",
    "fdaStatusNotes": "Offered as laboratory service from Burning Rock Dx laboratory in Guangzhou, China. Not available in US market.",
    "reimbursement": "Not established (China/International)",
    "reimbursementNote": "Primarily serves Chinese and international markets. US reimbursement not applicable.",
    "clinicalAvailability": "Commercially available in China and international markets via Burning Rock Dx laboratory.",
    "clinicalAvailabilityNotes": "Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR) is headquartered in Guangzhou, China.",
    "clinicalAvailabilityCitations": "https://www.brbiotech.com/ | https://ir.brbiotech.com/",
    "availableRegions": ["China", "International"],
    "availableRegionsNotes": "Primary market is China. International availability through central laboratory services.",
    "clinicalTrials": "NCT03634826 (MEDAL study); NCT05213312; NCT03937362; NCT06143644; NCT05244213; NCT05024266",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT03634826 | https://doi.org/10.1016/j.ccell.2023.08.010 | https://pubmed.ncbi.nlm.nih.gov/40375301/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11293361/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11163755/",
    "clinicalSettings": ["Post-Surgery", "Surveillance", "Neoadjuvant Response"],
    "clinicalSettingsNotes": "Validated for post-surgical MRD detection, longitudinal surveillance, and assessment of neoadjuvant therapy response. OSCC study showed utility in guiding adjuvant immunotherapy decisions.",
    "bloodVolume": ">16",
    "bloodVolumeNotes": ">16ml blood volume required per vendor.",
    "totalParticipants": 871,
    "numPublications": 8,
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/37683638/ | https://doi.org/10.1016/j.ccell.2023.08.010 | https://pubmed.ncbi.nlm.nih.gov/40375301/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC12490249/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11293361/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11163755/",
    "numPublicationsNotes": "8 publications including: Chen et al., Cancer Cell 2023; Molecular Cancer (OSCC, 2025); and ASCO/AACR conference presentations.",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "Clinical LDT offered from Burning Rock laboratory in China. Not FDA-approved; primarily serves Chinese and international markets.",
    "technologyDifferentiator": "Personalized tumor-informed MRD assay from leading Chinese NGS company. 100,000x ultra-deep sequencing with LoD of 0.004%. Demonstrated 299-day median lead time vs imaging in NSCLC. Head-to-head comparisons show superior performance vs tumor-agnostic and tumor-informed fixed-panel assays.",
    "vendorRequestedChanges": "2025-12-22: Initial entry created based on vendor submission from Liankai Chi (Burning Rock Dx). Performance metrics from submission and Cancer Cell 2023 publication (Chen et al., PMID 37683638). | 2025-12-24: Vendor validation with edits - updated clinicalTrials (+5 NCTs), numPublications (3→8), totalParticipants (181→871), added bloodVolume (>16ml)."
  },
  {
    "id": "mrd-kit-1",
    "sampleCategory": "Bone Marrow/Blood",
    "sampleCollectionNotes": "Primarily bone marrow; peripheral blood accepted for CLL",
    "name": "clonoSEQ Assay",
    "vendor": "Adaptive Biotechnologies",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina MiSeqDx",
    "approach": "Tumor-informed",
    "method": "NGS-based immunosequencing of IgH/IgK/TCR rearrangements; tracks patient-specific clonotype from diagnosis sample",
    "cancerTypes": [
      "Multiple Myeloma",
      "B-ALL",
      "CLL",
      "Mantle Cell Lymphoma"
    ],
    "indicationsNotes": "First and only FDA-cleared IVD for MRD detection. Indicated for hematologic malignancies only. CE-IVDR certified in EU.",
    "distributionNotes": "US: Primarily central lab service (send-out to Adaptive). EU: IVDR-certified reagent kit available for tech transfer to qualified laboratories.",
    "sensitivity": 95,
    "sensitivityCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170080.pdf | https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/",
    "sensitivityNotes": "Detects MRD at 10^-6 sensitivity in bone marrow samples. FDA-cleared analytical sensitivity. Concordance with flow cytometry 97.4% for ALL and 97.9% for MM.",
    "specificity": 99,
    "specificityCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170080.pdf | https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/",
    "lod": "1 cell in 1 million",
    "lodCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170080.pdf",
    "lod95": "10^-6",
    "lod95Citations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170080.pdf | https://pmc.ncbi.nlm.nih.gov/articles/PMC7325652/",
    "lodNotes": "Ultra-sensitive detection using immunosequencing of clonal rearrangements; depth limited by cell input.",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires diagnostic sample to identify patient-specific clonotype for tracking",
    "requiresMatchedNormal": "No",
    "initialTat": 7,
    "followUpTat": 7,
    "bloodVolume": null,
    "bloodVolumeNotes": "Primarily bone marrow; peripheral blood accepted for CLL",
    "fdaStatus": "FDA-cleared IVD (2018); CE-IVDR (2024)",
    "reimbursement": "Medicare LCD (MolDX); expanded coverage for MM, B-ALL, CLL, MCL",
    "cptCodes": "0364U",
    "clinicalAvailability": "FDA-cleared IVD kit; also available as central lab service",
    "totalParticipants": 50000,
    "numPublications": 200,
    "numPublicationsPlus": true,
    "clinicalSettings": ["Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Primarily used for post-treatment response assessment and ongoing surveillance in hematologic malignancies. Supported by NCCN guidelines for MM, ALL.",
    "technologyDifferentiator": "Only FDA-cleared MRD IVD kit. Unique immunosequencing approach tracks clonal Ig/TCR rearrangements rather than somatic mutations. Available as distributed IVD kit for labs with MiSeqDx, enabling in-house testing."
  },
  {
    "id": "mrd-kit-2",
    "sampleCategory": "Bone Marrow/Blood",
    "name": "LymphoTrack Dx IGH Assay",
    "vendor": "Invivoscribe",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina MiSeq",
    "approach": "Tumor-informed",
    "method": "NGS-based B-cell clonality and MRD tracking via IGH gene rearrangements",
    "cancerTypes": [
      "B-cell lymphomas",
      "CLL",
      "B-ALL"
    ],
    "indicationsNotes": "CE-IVDR marked for B-cell clonality assessment and MRD tracking in B-cell malignancies. Part of LymphoTrack portfolio including IGK and TRG assays.",
    "sensitivity": 98,
    "sensitivityCitations": "https://www.invivoscribe.com/products/lymphotrack-dx-igh-assay-miseq",
    "sensitivityNotes": "98% detection rate for clonal IGH rearrangements vs PCR GeneScan/Sanger sequencing; MRD sensitivity up to 10^-6 with sufficient DNA input",
    "specificity": 99,
    "specificityCitations": "https://www.invivoscribe.com/products/lymphotrack-dx-igh-assay-miseq",
    "specificityNotes": ">99% specificity for clonality detection per NGS validation studies",
    "lod": "10^-4 to 10^-6",
    "lodCitations": "https://www.invivoscribe.com/products/lymphotrack-dx-igh-assay-miseq",
    "lodNotes": "Sensitivity depends on DNA input and sequencing depth; can achieve 1 in 1 million with optimized protocols",
    "requiresTumorTissue": "Yes",
    "requiresTumorTissueNotes": "Requires diagnostic sample to identify clonal IGH rearrangement",
    "requiresMatchedNormal": "No",
    "initialTat": 5,
    "followUpTat": 3,
    "fdaStatus": "CE-IVDR; FDA clearance pending",
    "reimbursement": "Coverage varies; often reimbursed as clonality assay",
    "clinicalAvailability": "CE-IVD kit; RUO in US",
    "totalParticipants": 5000,
    "numPublications": 30,
    "clinicalSettings": ["Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Used for both initial clonality assessment and longitudinal MRD monitoring in B-cell malignancies.",
    "technologyDifferentiator": "CE-IVDR distributed kit enabling in-house NGS-based MRD. Works with MiSeq platform already common in molecular labs. Includes MyInformatics software for MRD trending."
  },
  {
    "id": "mrd-kit-3",
    "sampleCategory": "Bone Marrow",
    "name": "BD OneFlow B-ALL MRD Kit",
    "vendor": "BD Biosciences",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "BD FACSLyric Flow Cytometer",
    "approach": "Tumor-naïve",
    "method": "Multiparameter flow cytometry (Next Generation Flow); 8-color standardized panel for B-ALL MRD",
    "cancerTypes": [
      "B-ALL"
    ],
    "indicationsNotes": "CE-IVDR marked standardized flow cytometry MRD kit for B-cell ALL. Part of EuroFlow consortium standardization.",
    "sensitivity": 96,
    "sensitivityCitations": "https://www.bd.com/en-us/products-and-solutions/products/product-families/bd-oneflow-b-all-mrd-kit",
    "sensitivityNotes": "96% sensitivity for MRD detection at 10^-4 threshold (EuroFlow standardized protocols); sensitivity of 10^-4 to 10^-5 depending on cell events acquired",
    "specificity": 95,
    "specificityCitations": "https://www.bd.com/en-us/products-and-solutions/products/product-families/bd-oneflow-b-all-mrd-kit",
    "specificityNotes": "95% specificity vs final clinical diagnosis in validation studies",
    "lod": "10^-4 to 10^-5",
    "lodCitations": "https://www.bd.com/en-us/products-and-solutions/products/product-families/bd-oneflow-b-all-mrd-kit",
    "lodNotes": "Flow cytometry sensitivity depends on number of events; typically 10^-4 with 1 million cells",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Tumor-naïve approach - no prior sample needed",
    "requiresMatchedNormal": "No",
    "initialTat": 1,
    "followUpTat": 1,
    "fdaStatus": "CE-IVDR; not FDA-cleared",
    "reimbursement": "Coverage as flow cytometry MRD",
    "clinicalAvailability": "CE-IVD kit",
    "totalParticipants": 10000,
    "numPublications": 100,
    "numPublicationsPlus": true,
    "clinicalSettings": ["Post-Adjuvant", "Surveillance"],
    "clinicalSettingsNotes": "Same-day results enable rapid treatment decisions. Standard of care for MRD monitoring in many European centers.",
    "technologyDifferentiator": "Flow cytometry provides same-day results vs. 5-7 days for NGS. Standardized EuroFlow panels ensure reproducibility across labs. No prior sample needed (tumor-naïve). Different modality than NGS - may be complementary."
  }
]